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ABSTRACT
In cases of metastatic melanoma, BRAF is frequently mutated to the V600E
oncoprotein causing uncontrolled cell proliferation driven by the MAPK-ERK pathway.
There are several BRAF inhibitors, such as vemurafenib, which are FDA approved, but
patients treated with these Type-I kinase inhibitors frequently observe relapse under
mutant RAS and BRAF-wt conditions due to paradoxical activation. The mechanism of
this resistance occurs through binding of the inhibitor to BRAF-wt initiating
conformational changes which leads to BRAF dimerization. Once in the dimerized state,
the inhibited monomer induces allosteric transactivation of the second monomer. This
drug-induced activation of BRAF in cells with mutant RAS leads to uncontrolled cellular
proliferation. In the context of mutant RAS/BRAF-wt cells treated with Type-I inhibitors,
the MAPK/ERK pathway continually signals for initiation of cell proliferation, leading to
mutant RAS-driven tumorigenesis. Currently there are no FDA approved treatments on
the market for inhibiting RAS-driven tumorigenesis directly due to RAS family members
having picomolar affinity for GDP/GTP. Recently there has been some progress in clinical
trials of AMG510 (sotorasib), which binds outside of the catalytic GDP/GTP binding site.
In a small cohort of 13 patients with KRAS-G12C-driven tumors, 7 patients observed
partial responses to the target dose and 6 had stable disease.1,64 Though this clinical trial
is exciting there is still a need for therapies targeted toward preventing paradoxical
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activation in melanoma patients and for alternative therapies for patients suffering from
mutant RAS-driven tumorigenesis. Herein we discuss the linear design of potent Type-IV
BRAF inhibitors which have been seen to inhibit paradoxical activation of mutant
RAS/BRAF-wt driven tumorigenesis.
Initially, the linear native sequence of peptides from the BRAF dimer interface
(DIF) and variations of this were tested for direct binding using an intrinsic tryptophan
fluorescence assay. Contributions of residue sidechains was further assessed through an
alanine-scan of the truncated, linear sequence. Linear data combined with the crystal
structure (PDB 4E26) contributed to the design of a 6-residue macrocyclic peptide which
possessed enhanced binding. These alterations enhanced binding interactions giving a
peptide with Kd=0.06µM compared to the native sequence with Kd=3.84 µM.
Cyclic peptides were then optimized to include physiochemical properties which
agree with the beyond the rule of 5 guidelines for passive cell permeability of macrocycles
larger than 500 Da. Further modifications consisted of REPLACEment of exocyclic
sequences with more drug-like analogs which are uncharged and lipophilic in nature.
Additional derivatization included N-methylation of the peptide backbone.

The

macrocyclic peptidomimetics described herein represent potential next generation BRAF
therapeutics which have potent binding and have anti-tumor activity under paradoxical
activation conditions.
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CHAPTER 1
INTRODUCTION
1.1 Historical Perspective on Cancer Treatment
The collective disease state of cancer is characterized as an uncontrolled
proliferation of cells due to mutations in the genetic code. These mutations can then lead
to changes in the conformation of proteins whose role is to regulate cell proliferation and
programed cell death known as apoptosis.

With deregulated cell division and/or

apoptosis, such mutations can lead to tumorigenesis and form tumors. In the case of
malignant cancer types, these cells can break away from the original mass and travel to
distant and unrelated areas of the body to start new tumors in other locations.
Tumorigenesis in organs responsible for life sustaining functions, such as nutrient
absorption in the intestines or gas exchange in the lungs, can become deadly by disrupting
the function of that organ system. According to predictions published by the American
Cancer Society, there will be an estimated 1.8 million new cases and about 600 thousand
deaths from cancer in the United States alone in 2020; of which 5.5% of the predicted
new cases (100,350 cases) are attributed to melanoma of the skin, with about 11,500
cases of skin cancer resulting in death.3
Chemotherapy refers to the treatment of a disease with a chemical drug, although
the word is now usually most associated with cancer treatment specifically. The use of
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chemotherapy drugs is a way of treating the whole body with the intent to cure, control,
or ease the symptoms of a patient’s disease state.2 Furthermore, modern chemotherapy
is usually administered as a neoadjuvant therapy i.e. to shrink the tumor prior to surgery
or radiation treatment either due to size of the tumor or complexity around vital organs.
Additionally, it can be used as an adjuvant therapy after surgery to prevent the
reappearance of the resected tumor.
Traditional cancer chemotherapeutic drugs typically target the cell cycle. Many of
the traditional drugs have been in use for decades starting with the discovery of the
nitrogen mustards and the anti-metabolites in the 1940's.3 These drugs are classified into
several classes: alkylating agents, antimetabolites, anti-tumor antibiotics, topoisomerase
inhibitors, and mitotic inhibitors,3 and are toxic because they mostly target DNA similarly
in normal and cancer cells. Although these drugs have the benefit of treating the whole
body in contrast to the local treatments of surgery or radiation therapy, the risk factors
associated with chemotherapy include the eminent danger of harming the normal,
healthy cells and the potential incidence of leukemia and nerve or heart damage. 3
1.2 Targeted Therapy of Kinases
In contrast to “chemotherapy”, targeted therapy involves treating cancer patients
based on their individualized type of cancer and the product of specific mutations which
lead to constitutively active proteins or changes in protein levels which inherently cause
the uncontrolled cell proliferation.5 In this sense, cells bearing specific cancer markers,
containing upregulated protein levels, or mutations which enhance drug binding would
2

be affected solely or more significantly, therefore leaving the normal, healthy cells
relatively unharmed. The product of the oncogene is targeted in this sense because the
protein products are significantly different due to conformation, whereas the mutant
verses non-mutant DNA is relatively similar. For example, trastuzumab is a monoclonal
antibody which is used in the treatment of postmenopausal women who have HER2+
breast cancer.6

This antibody specifically binds to the HER2 receptor, which is

overexpressed in 20-30% of breast cancer cases due to having extra copies of the gene
encoding HER2. Due to the overexpression of the HER2 receptor, these cells are more
susceptible to treatment with trastuzumab verses normal cells.
The kinase superfamily is a large group of proteins whose catalytic activity
functions by phosphorylating its substrate, thus acting as a signal transducer. But kinases
also have a large role in the non-catalytic, coordination of complex biological processes
by scaffolding protein complexes, acting as competition for protein interactions, exerting
allosteric effects on other enzymes, subcellular targeting, and DNA binding.7,8 For
catalytic signaling of protein kinases, an upstream protein will bind to the kinase and
phosphorylate the activation loop, thus converting the kinase to its active conformation.
In the presence of ATP, a kinase can bind and phosphorylate the downstream substrate
by adding a phosphate to the substrate serine, threonine, or tyrosine residue, depending
on the class of kinase, while converting the ATP to ADP, thus either activating or inhibiting
the target substrate’s catalytic activity. In this sense, a phosphorylation cascade can
propagate, and a signal can be conveyed from one portion of the cell to another and a
response can be triggered. Furthermore, kinases not only can propagate a signal, but
3

catalytic activity of kinases can inversely inhibit cellular functions as well. In the cancer
disease state kinases which promote cell proliferation and survival can become
dysregulated and continually signal, thus promoting tumorigenesis and making them ideal
targets of therapeutic intervention for inhibiting the uncontrolled signaling from
oncogenic kinases. Furthermore, kinases consume adenosine triphosphate (ATP) for
catalytic activity by cleaving the γ-phosphate for phosphorylation of its substrate.
Historically, most kinase drug discovery involves the design of a small molecule which
binds to the ATP binding site with higher affinity than the native substrate to prevent the
kinase’s catalytic activity, this is the mechanism for Type I-III inhibitors as described
below. Overall, the benefits of inhibiting a kinase would be the ability to directly interfere
with the dysregulated pathway which drives tumorigenesis by means of small molecule
inhibitors. Potential drawbacks of this approach include lack of selectivity for more than
500 known kinases encoded by the genome, with similar ATP binding pockets. Therefore,
kinase inhibitors utilizing the ATP binding site have the potential to have off-target effects
which may be counterproductive to the therapeutic intent.
Kinase inhibitors are chemical compounds with the therapeutic ability to interfere
with kinase activity. The first clinical approval for use of a kinase inhibitor was the
approval of fasudil in Japan for the indication of patients suffering from cerebral
vasoplasm.9 Later, the drug was determined to be inhibiting Rho kinase II which prevents
activation of pathways controlling vascular smooth muscle contraction.10 In 2001, the
first US FDA approved kinase inhibitor in oncology was imatinib (Gleevec) used for the
treatment of chronic myelogenous leukemia (CML).11 After the 5 year follow-up on
4

patients initially treated with imatinib, the majority of patients maintaining a continuous
therapy of imatinib treatment had a complete cytogenetic response (P<0.001) and there
was minimal risk of disease progression.12 Furthermore, continuous treatment with
imatinib from initial diagnosis produced a survival rate of 89% which is higher than that
of any prior study of CML treatment. Currently there are 48 US FDA approved small
molecule kinase inhibitors, most of which are orally bioavailable and are indicated for
treatment of malignancies.13 For a compound to inhibit a kinase, the compound must be
able to bind to either the ATP binding site, co-factor binding site, or a regulatory proteinprotein binding site.

Currently there are six types of kinase inhibitors which are

categorized by their mechanism of inhibition and they are defined as follows:14
•

Type I: Bind to the active conformation (DGF-in/αC-in) and occupy some of the
ATP binding site with hydrogen bonds to the hinge region

•

Type I ½: Bind to the inactive conformation (DGF-in) and occupy some of the ATP
binding site with hydrogen bonds to the hinge region

•

Type II: Bind to the inactive conformation (DGF-out) and occupy some of the ATP
binding site with hydrogen bonds to the hinge region

•

Type III: Bind adjacent to the ATP binding site and allosterically blocks ATP from
binding.

•

Type IV: Bind to an allosteric site which is not the ATP binding site nor the
substrate binding site

•

Type V: Bivalent compounds which bind to two different sites of the enzyme
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Stratification of types of kinase inhibitors has to do with selectivity as well as
combatting disease resistance mechanisms. As for selectivity, a mutation may cause the
target to be locked in the active conformation, thus a Type II inhibitor would not work
since it binds to the inactive conformation. Furthermore, if treatment with a Type I
inhibitor leads to dimerization dependent resistance, then an allosteric Type IV inhibitor
may be of use to combat the resistance mechanism by blocking dimerization.
1.3 MAPK Pathway
The mitogen-activated protein kinase (MAPK)/ERK pathway is responsible for cell
proliferation and differentiation in the cell.15–17 Through this pathway, extracellular
signals are carried to nucleus to initiate transcription of proteins necessary for cell
proliferation. The principal proteins associate with this pathway are RAS, RAF, MEK, and
ERK.
Signal transduction is initiated upon binding of extracellular growth factors (e.g.
epidermal growth factor) to their respective receptor tyrosine kinase (RTK; e.g. epidermal
growth factor receptor). This leads to the recruitment of guanine nucleotide exchange
factors to the cell membrane to facilitate the exchange of GDP for GTP on the membrane
localized RAS protein (KRAS, NRAS, or HRAS)(Figure 1.1). This exchange activates the RAS
protein and allows it to bind to a RAF monomer (ARAF, BRAF, or CRAF). Once the RASGTP-RAF complex is formed, the RAF catalytic domains associate through the dimerization
interface (DIF).

The activation site of one protomer is phosphorylated, causing

conformational changes in the regulatory spine (R-spine) and DIF, resulting in the
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phosphorylation of the second protomer in the dimeric complex. The dimeric form of RAF
kinase is catalytically active and initiates the phosphorylation cascade on to MEK and ERK,
which ultimately activates the downstream transcription factors required for cell
proliferation.18
The MAPK/ERK pathway is largely involved in cell proliferation, differentiation,
and survival of the cell, therefore, members of this pathway frequently are dysregulated
in cancer. Upstream abnormalities include frequently overexpressed or mutated RTK’s
which can lead to an increased degree of signaling due to growth factor binding.19–21
Furthermore, activating mutations in the RAS GTPase22–24 which functions as a molecular
switch are frequently observed as well, leading to the activation of the MAP3K (RAF) for
this signaling pathway. Downstream influences include the loss of neurofibromin 25, the
protein product of the NF1 gene which is a negative feedback mechanism of the
MAPK/ERK pathway. NF1 is a tumor suppressor protein which is transcribed by the
MAPK/ERK pathway and inhibits the activity of RAS. Loss of this NF1 gene removes the
negative feedback regulation step and can be a factor of tumorigenesis by dysregulating
upstream catalytic enzymes. Furthermore, RAF acts as the gatekeeper kinase of the
MAPK/ERK pathway and gain-of-function point mutations are frequently observed in
malignancies.18,26,27

Dysregulation of this kinase allows for the initiation of the

phosphorylation cascade and thus uncontrolled cell proliferation. The most frequent RAF
mutation is the BRAF V600E point mutation which mimics activation loop
phosphorylation26,28, thus allowing the kinase to not only function without upstream
activation, but it also allows the kinase to have catalytic activity as a monomer. This
7

mutation removes two of the regulatory mechanisms from the native kinase, locking it in
the active conformation and producing uncontrolled activity, thus leading to
tumorigenesis.
The RAF kinase has three isoforms in the human context, ARAF, BRAF, and RAF-1
(i.e. CRAF). The RAF kinases all share three highly conserved regions:
•

CR1: RAS-GTP binding domain (RBD) and Cysteine-rich domain (CRD)

•

CR2: 14-3-3 protein binding site

•

CR3: Catalytic domain and Dimer interface (DIF)

The CR1 RBD contains a conserved arginine residue (R188 in BRAF) which facilitates
its recruitment to the membrane and RAS-GTP binding.26 Mutation of this residue
(R188L) inhibits upstream activation via RAS interaction and abrogates downstream
phosphorylation events. The 14-3-3 protein binds to phosphorylated S365 in BRAF in the
CR2 and stabilizes the inactive, closed conformation in which the N-terminal and Cterminal domains are clamped together.26 Dissociation of this protein and subsequent
dephosphorylation of the serine residue represents a key regulatory step in BRAF
activation, opening up the conformation for RAS-GTP binding. The catalytic CR3 domain
contains the N-region, Phosphorylation Loop (P-Loop), Activation Loop (A-Loop), and the
DIF, where the latter facilitates the side-to-side dimerization step required for RAF
activation. One protomer of the loosely dimerized RAF kinase has its activation site
(T599VKS602) phosphorylated which causes a conformational change, involving the
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regulatory spines and dimer interface and then leads to allosteric phosphorylation of the
second, inactive protomer and a fully active RAF complex.18,26
In cases of metastatic melanoma, as well as hairy cell leukemia and colorectal
carcinoma29, BRAF is mutated in about 45% of cases30 with the most frequent being the
V600E point mutation. This substitution mimics BRAF phosphorylation by introducing a
negatively charged glutamate residue near the point of phosphorylation on the activation
loop, rendering the kinase locked in a constitutively active conformation. By mimicking
the A-loop phosphorylation, the monomer is without need of RAS binding and can initiate
the phosphorylation cascade without extracellular initiation.
1.4 Paradoxical Activation and Resistance
In 2011, the FDA-approved drug Zelboraf® (vemurafenib)15, was approved for the
indication of melanoma patients bearing the BRAF V600E mutation. This drug is a Type I ½
kinase inhibitor which potently binds to the ATP binding site of mutant BRAF V600E and
initially created significant enthusiasm by therapeutically reducing the tumor size in
patients exhibiting this mutation. This enthusiasm diminished as drug-induce resistance
appeared in patients after 23 weeks of treatment with the drug.31 This resistance was
later identified as paradoxical activation, in which the drug would inhibit ATP binding to
the first protomer of BRAF-wt protein in the presence of oncogenic RAS but induce
catalytic activity of the second protomer in the dimeric RAF complex.32–34 In these cases,
oncogenic RAS allowed for unregulated signaling through the now activated BRAF
protomer, resulting in proliferation of undruggable, mutant RAS-driven tumors.
9

The undesirable clinically observed response to vemurafenib sparked the drive to create
second line therapies for patients who have developed resistance for the drug. The FDA
approval of the MEK inhibitor trametinib as a combination therapy for patients with
mutant melanoma yielded significant improvement, but MEK inhibitors have toxicity
issues which make treatment difficult.11 The idea behind this combination was to target
the initial BRAF-driven tumor with vemurafenib, and then to inhibit drug-induced
progression of upstream RAS-driven tumorigenesis by inhibiting the downstream MEK
kinase. Furthermore, the sequential combination of BRAFi/MEKi therapy followed by
immunotherapy with the anti-CTLA4 antibody imilmumab or anti-PD1 antibodies
nivolumab and pembrolizumab has yielded improvements but not without multiple
mechanisms of escape from immunotherapy.35 For this combination, adjuvant therapy
with either anti-CTL4 or anti-PD1 antibodies allows for the production and immune
response via T-cells which have the ability to kill cancer cells. The idea is that after initial
treatment with small molecule inhibitors, immunotherapy activates the T-cells to attack
overly prolific cells, thus maintaining a smaller tumor size and increasing the survival rate
of the patient.
1.5 Hypothesis and Rationale
The drug-induced dimerization of BRAF-wt and proliferation of mutant RAS-driven
tumorigenesis can be inhibited by a macrocyclic, Type IV kinase inhibitor designed around
the reverse β-turn sequence (Figure 1.2) of the BRAF dimer interface. In the treatment
of BRAF V600E mutant melanoma, there is also a high frequency of mutations leading to
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oncogenic RAS, i.e. about 30% of all human cancers.29 In previous attempts to treat
patients with this mutation, Type I BRAF inhibitors proved to be effective in the mutant
BRAF context, but in the wild-type BRAF context, the inhibitor induced BRAF homo/heterodimerization and subsequent paradoxical activation of the second monomer. In
the case of the presence of oncogenic RAS and wild-type BRAF, a drug-resistant tumor
forms, for which there is not effective therapy. The treatment of patients with the
proposed Type IV BRAF DIF inhibitor should prevent the paradoxical activation of BRAF
and therefore avoid the promotion of the RAS-driven tumor while treating with
vemurafenib.
1.6 Rationale for targeting the dimer interface of RAF kinases
In 2001, the significance of RAF heterodimerization was demonstrated for the first
time;36 then there was the discovery that the naturally occurring R732H mutation, in
Drosophilia KSR (Kinase Suppressor of RAS), which abolished KSR-induced RAF activation
and subsequent MEK phosphorylation in S2 cells.37

Based on that discovery,

Rajakulendran et al. described the side-to-side dimerization of RAF/KSR and deemed the
BRAF DIF a potential therapeutic target.38 This work was based on the analysis of KSR and
RAF crystal structures, from which R732 of KSR was found to be conserved throughout
the KSR and RAF kinase families. Further investigation of the crystal structures showed
that KSR and BRAF have similar dimer interfaces and through dimerization, R732 of KSR
engages the αC-helix of BRAF, a known regulatory structure required for catalytic activity.
Furthermore, in an analytical ultracentrifugation experiment, DRAF-wt (RAF isoform of
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Drosophila) was able to form dimers, whereas DRAF-R481H (equivalent to KSR R732H)
was only found as a monomer in solution, thus demonstrating the dimer inhibitory effects
of the R481H mutation. Dimerization was further identified as a key step to catalytic
activity in a KSR-RAF-MEK co-overexpression assay where mutations in either the KSR or
RAF dimer interface abrogated MEK (direct catalytic substrate of RAF) phosphorylation,
whereas mutations distant from the DIF did not, thus further demonstrating the catalytic
relevance of RAF dimerization for activity.
Roring et al. has done extensive work with characterizing the BRAF dimer interface
and has further identified binding determinants for BRAF homo-/heterodimers through
cellular studies analyzing substrate level phosphorylation of downstream targets.26 The
DIF is described as a central cluster of residues in the form of a reverse-β-turn located
between the αC-helix and the β4-sheet (Figure 1.2). The R481H substitution (R509H in
BRAF) in DRAFEVKD, a synthetic mutant with similar as activity to BRAF V600E, was shown
to ablate downstream MEK phosphorylation according to Rajakulendran et al. 38 Roring
et al. found that the BRAF-R509H substitution and the 3x mutant (3x: R509H, L515G, and
M517W) had a similar inhibitory effect in the BRAF-wt context with a reduced cellular
MEK phosphorylation potential of >60 and 90%, respectively, but Class I high activity
BRAF-V600E, BRAF-insT, and BRAF-G469A were insensitive to the DIF mutations.26
Furthermore, BRAF DIF mutations inhibited paradoxical MEK/ERK phosphorylation
induced by D594A mutation, sorafenib, or PLX 4720, but heterodimerization with CRAF
was not abolished, which suggests that inhibition of the dimerization motif could be a
therapeutic target to combat drug-induced paradoxical activation of BRAF-wt.
12

Additionally, although the CRAF-R401H (equivalent to BRAF-R509H) mutation impaired
MEK phosphorylation, CRAF homodimers were still formed, suggesting that RAF
activation consists of a two-step mechanism consisting of dimerization and then DIFmediated transactivation. This data directly supports the idea that disruption of the DIF
in the BRAF-wt context can prevent downstream MEK phosphorylation events and
provide an alternative therapeutic for preventing mutant RAS-driven tumorigenesis
during the treatment of patients bearing the BRAF-V600E mutation.
In a study conducted by Freeman et al., RAF heterodimerization versus
homodimerization was explored among the three RAF isoforms.39 In this study, it was
found that BRAF and CRAF heterodimerization was the major activating complex for MEK
phosphorylation, and ARAF had only marginal heterodimerization with BRAF, but not
CRAF. Heterodimerization of BRAF/CRAF was observed to be more crucial for CRAF
activity when removal of BRAF decreased CRAF-driven activity by 90% compared to basal
level. In the reverse case, removal of CRAF only decreased BRAF-driven activity by 50%.
Furthermore, BRAF was shown to exhibit some homodimerization, as well as CRAF
homodimerization was observed to a lower extent. Additionally, through the use of
mutational experiments, alterations in the BRAF and CRAF dimer interface were tested
for catalytic activity in which the R509H mutation previously shown to inhibit BRAF
catalytic activity was confirmed for both BRAF and CRAF (R401H), of which the CRAF
mutant also exhibited a decreased basal level activity, whereas BRAF was only an
inhibition of EGF-induced activity. This mutation was also demonstrated to inhibit
BRAF/CRAF homodimer activity as well. Additionally, as a primary proof-of-concept for
13

the use of DIF peptides as dimerization inhibitors, the GFP-tagged DIF peptide, GFP-DI1
(GVLRKTRHVNILLFMGYST),

was

expressed

in

cells

and

inhibited

BRAF/CRAF

heterodimerization as well as RAF-mediated MEK phosphorylation. Moreover, NSCLC
cells were treated with TAT-DI1, and was shown to inhibit cell viability compared to the
TAT-Scram negative control peptide (GRINKGRHTFLLVVMTYSL).

Taken together,

heterodimerization of BRAF and CRAF appears to be the driving force for RAF-catalyzed
MEK phosphorylation and this work is the first to demonstrate the ability to inhibit MEK
phosphorylation using a BRAF DIF peptide sequence.
While this research was being accomplished, there was another article published
by Gunderwala et al. which provides a secondary proof-of-concept for the approach of
inhibiting BRAF dimerization using DIF peptides.40 In this study, linear DIF peptides
(Braftide; BRAF residues 508-517; TRHVNILLFM) were computationally designed and
tested for their ability to inhibit full length BRAF catalytic activity in solution using the
ELISA assay. The data was obtained by measuring MEK phosphorylation and resulted in
IC50 = 364 nM and 172 nM for BRAF-wt and BRAF-G469A, respectively. Mutation of the
arginine residue in the braftide to histidine (R/H-braftide; THHVNILLFM) resulted in data
consistent with findings from Roering et al. with IC50 = 1.5 µM and 2.5 µM for wild-type
and G469A respectively. Furthermore, TAT-Braftide constructs in the BRAF-wt and nonV600 BRAF mutant (BRAF-G469A) context using HEK293 cells transfected with the protein
of interest were tested as a cellular experiment while being co-treated with dabrafenib,
a type I BRAF kinase inhibitor. This data confirms the ability of DIF peptides to inhibit MEK
phosphorylation under the paradoxical activation conditions as well as its application in
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treatment of cancer driven by non-V600 BRAF mutants. Interestingly, BRAF and MEK
were observed to be proteolytically degraded upon treatment with TAT-Braftides, the
authors attributed this to a non-catalytic function of BRAF kinase. Furthermore, the TATBraftides were tested for cell viability in HCT116 and HCT-15 cell lines, which both contain
the KRAS-G13D gain-of-function mutation, while cells were co-treated with clinically
relevant BRAF inhibitors. The resulting EC50 = 7.1 and 6.6 µM respectively, with the TAT
sequence alone acting as the negative control with no observable cell death up to 100
µM, demonstrating that DIF peptides can inhibit mutant RAS-driven tumorigenesis in the
clinically relevant paradoxical activation context. Taken together, this data demonstrates
the proof-of-concept for the inhibition of paradoxical activation using BRAF DIF inhibitors
to dissociate BRAF homo-/heterodimers of BRAF-wt for the clinical application of
preventing drug-induced resistance to type I BRAF kinase inhibitors.
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FIGURE 1.1: MAPK PATHWAY SIGNALING SCHEME: Extracellular signaling
initiates the MAPK pathway by binding of EGF to EGFR, thus activating the
SOS complex to catalyze the exchange of GDP for GTP on membrane
localized RAS protein. RAS then phosphorylates a RAF isoform, triggering
dimerization and propagation of the phosphorylation cascade through
MEK and ERK to activate transcription factors in the nucleus and eventually
lead to cell proliferation.
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FIGURE 1.2: DIF PEPTIDE MIMICKING REVERSE-BETA-TURN OF NATIVE SEQUENCE:
Solvent surface of BRAF homodimer crystal structure where the DIF peptide (blue) is
truncated from BRAF (grey) native sequence to bind the target BRAF (cyan). Key linear
residues R509 (magenta), H510 (orange), and L515 (green) highlighted in linear sequence
and ATP (yellow) highlighted for perspective.
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CHAPTER 2
LINEAR BRAF DIF PEPTIDES INHIBIT PARADOXICAL ACTIVATION
2.1 Introduction
The MAPK/ERK pathway, controls cell proliferation and differentiation and in the
cancer disease state, this pathway frequently encounters gain-of-function mutations
which dysregulate signaling and lead to tumorigenesis. Of these mutations, RAF-driven
malignancies have a high frequency in cases of metastatic melanoma, to which Type I
kinase inhibitors have been FDA approved, but unfortunately lead to the resistance
mechanism know as paradoxical activation which is catalyzed by stabilization of the active
conformation of the drug-free protomer in the dimeric complex of wild-type BRAF
through the BRAF dimer interface. In cases of metastatic melanoma there is also a high
frequency of oncogenic RAS, and through this mechanism oncogenic RAS-driven
tumorigenesis can proliferate through dysregulation of the gatekeeper BRAF kinase, thus
leading to a tumor type of which the driving oncogenic protein has no efficient
therapeutics.
Previous studies outlined in Chapter 1 have demonstrated the requirement of the
dimer interface for paradoxical activation and have started the development of peptidic
BRAF dimer interface inhibitors using the native sequence as a proof-of-concept for
therapeutically inhibiting BRAF dimerization and thus preventing the paradoxical
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activation mechanism. In the following chapter, the use of DIF peptides for the inhibitor
of clinically relevant disease-state signaling will further be demonstrated using cellular
studies exhibiting inhibition of substrate level phosphorylation as well as inhibition of cell
viability. Furthermore, the BRAF-wt dimer interface and the contributions of DIF peptides
to binding will further be examined using a direct binding assay for a library of probing
linear peptides designed to explore the binding contributions of each peptidic residue.
For the initial design of the peptidic dimer interface inhibitors, inspirations were
brought in from literature-based peptides as well as in silico computational modeling. The
natural dimer interface sequence was probed by point mutations and an alanine-scan in
order to simulate the most favorable alterations to enhance binding potency.
Quantitative data from minimization and interaction energy calculations were
retrospectively fruitless, but based on the qualitative data obtained from the modeling
experiments, a linear peptide library was designed and ordered from GenScript for
experimental testing.

Linear peptides were tested using the intrinsic tryptophan

fluorescence (ITF) assay which measures direct binding of the peptide to BRAF-wt. The
experimental and computational data were compared to determine key binding
interactions of the DIF peptides with the dimer interface to facilitate the design of potent,
cyclic peptides for BRAF dimer inhibition (Chapter 3).
2.1.2 Crystal Structure
The crystal structure for the full length BRAF homodimer has recently been solved
(PDB 4e26) and was used in the design of the Type IV BRAF inhibitors using the Discovery
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Studio 3.0 software. The BRAF dimer interface is characterized as having a short,
continuous sequence consisting of BRAF residues 503-521 which form a reverse-β-turn
and facilitate the side-by-side dimerization of BRAF. Based on literature evidence, R509
is a key binding determinant as exemplified by mutational experiments described in
Chapter 1. Further inspection of this binding motif using the crystal structure revealed an
arginine-handshake motif where R509 binds to the induced negative charge of the αChelix of the complementary protein in a mirror-like fashion (Figure 2.1A). Further
examination of the DIF binding surface revealed a deep, lipophilic pocket directly adjacent
to the R509 binding site, to which L515 localizes (Figure 2.1B).

Based on initial

minimizations, H510 appears to be stabilizing the reverse-turn through an intramolecular
hydrogen bonding network involving the N512 side-chain and L514 backbone amide as
well as displaying hydrogen bonding interactions with the complementary H477
backbone carbonyl (Figure 2.1C). Other characteristics of the DIF binding surface utilize
hydrophobic residues such as V511, F516, and M517 which interact with the generally
hydrophobic binding surface (Figure 2.1D). These qualitative observations were directly
extrapolated from the 4e26 BRAF homodimer crystal structure and required further
quantitative analysis to more accurately characterized the landscape of the BRAF DIF
binding surface.
2.1.3 Direct Binding Assay
Experimental testing of the direct binding potency of the peptides to the BRAF-wt
dimer interface (DIF) was accomplished using the intrinsic tryptophan fluorescence (ITF)
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assay. There are other aromatic residues in proteins such as phenylalanine (Phe) but its
contribution is negligible due to low absorptivity and very low quantum yield, the ratio of
photons emitted verses photons absorbed. There is also tyrosine (Tyr), which has a
quantum yield similar to that of tryptophan (Trp), but the magnitude of Trp absorbance
is higher due to the indole group of the Trp sidechain being the dominant source of UV
absorption at 280 nm.41 Tryptophan when excited at 280 nm has a specific emission
wavelength at 350 nm and when solvent exposed on the protein emits a baseline
fluorescence. In the binding site of the DIF is W450, upon binding of the peptide to the
binding site, the micro-environment of W450 is changed and this residue is no longer
solvent exposed and the overall fluorescence of the BRAF protein after excitation at this
specific wavelength is reduced. With titration of the DIF peptide and the measured
decrease in intrinsic fluorescence at 350 nm, a dose-response curve was generated, and
the dissociation constant (Kd) was determined from each compound. Data from these
experiments gave quantitative experimental data to confirm binding determinants which
were previously predicted by the computational modeling of DIF peptides.
2.2 Results
2.2.1 Electroporated DIF Peptides inhibit BRAF-wt signaling under paradoxical
activation conditions
The nature of drug-induced paradoxical activation requires dimerization of BRAFwt to allow for the activation of the second monomer.32–34 In this case the BRAF-wt
homodimer forms as a side-by-side protein-protein interaction, of which the crystal
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structure has recently been solved (PDB: 4e26). The majority of the dimer interface is
composed of a single continuous sequence with no gaps, residues 503-521 (1; Figure 2.1),
which makes up the reverse-β-turn located between the αC-helix and the β4-sheet,
therefore allowing for a single peptide to be generated to inhibit BRAF dimerization. It
was hypothesized that treatment with a peptide representing this native sequence would
disrupt the BRAF-wt homodimer and therefore inhibit downstream phosphorylation
events in the paradoxical activation context.
In an experiment, conducted by the Brummer lab, to determine the effects of the
DIF peptide 1 on substrate level phosphorylation under the paradoxical activation
conditions, this peptide was synthesized. SBcl2 cells containing the NRAS Q61K gain-offunction mutation were electroporated in the presence of Peptide 1 and were then
treated with PLX4032 (vemurafenib) to simulate the paradoxical activation mechanism.
After lysis, immunoprecipitating, and western blotting, the result shows that Peptide 1
causes a dose dependent decrease of MEK and ERK phosphorylation in the presence of
PLX4032 and NRAS Q61K (Figure 2.2). In contrast, the positive control (lane 2) where the
NRAS Q61K mutant cells are treated with PLX4032 alone, there is an observed enhanced
phosphorylation of MEK and ERK compared to the baseline phosphorylation in lane 1
where the cells are treated with vehicle alone. These results suggest that inhibition of
downstream phosphorylation is due to the disruption of the BRAF-wt dimerization event
by Peptide 1 binding, and thus preventing the activation of the second monomer in the
presence of PLX4032. This data provides proof of concept for inhibition of downstream
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MEK/ERK phosphorylation by disruption of the BRAF-wt dimer interface by treatment
with a peptidic DIF inhibitor.
2.2.2 FAM-TAT-DIF Peptides inhibit cell viability in a dose-dependent manner
In an experiment, conducted by the Brummer lab, to investigate the effects of DIF
peptides on cell viability and visualize entry, N-terminal 5-carboxyfluoroscein (5-FAM)
labeled trans-activating transduction (TAT) fusion peptides were used to treat SbCl2
melanoma cells. As seen in Figure 2.3A, treatment of cells exposed to a 3.6 µM peptide
solution displayed fluorescence in contrast to the lower concentration which only
exhibited background autofluorescence. Cells treated with the active FAM-TAT-Pep17
peptide (BRAF 504-518, loop forming residues from DIF contact surface) tended to form
smaller colonies than the cells treated with the FAM-TAT-Pep6AlaNC3 (GRKKRRQRRR(PEG2)-GVLAATAAVNALLFAGYST) negative control (residues contacting the other
monomer mutated to alanine). Furthermore in the colony forming assay in Figure 2.3B,
it can be seen that treatment with FAM-TAT-Pep17 had an inhibitory effect as low as 1.8
µM with complete absence of colonies at 3.6 µM, whereas no inhibitory effect for FAMTAT-Pep6AlaNC3 was observed until cells were treated with the 7.2 µM solution.
2.2.3 FAM-TAT-DIF Peptides inhibit downstream substrates of ERK kinase
The Brummer lab performed further experiments using these FAM-labeled TATfusion peptides in same SbCl2 cells (NRAS-Q61K), co-treatment with FAM-TATPep6AlaNC3 and PLX4032 elicited an enhanced phosphorylation of MEK/ERK (Figure
2.3C). In contrast, treatment with FAM-TAT-Pep17 in the presence of PLX4032 exhibited
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a decrease of the enhanced downstream phosphorylation induced by PLX4032. To
monitor further downstream effects of MEK/ERK inhibition, the expression and
phosphorylation of FRA1 was analyzed. ERK directly activates the transcription of the
FOSL1 gene to make FRA1, and down regulation of this protein is thus a direct readout
for inhibition of ERK activity as would be expected by BRAF DIF peptides. As seen in Figure
2.3C, FAM-TAT-Pep17 downregulated the expression and phosphorylation of FRA1
compared to cells treated with FAM-TAT-Pep6AlaNC3, thus demonstrating inhibition of
ERK activity. Taken together, the data from these cellular studies supports the hypothesis
that BRAF DIF-based peptides can inhibit downstream phosphorylation events driven by
oncogenic RAS and PLX4032.
2.2.6 Experimental Testing of BRAF 503-521 Linear Peptide Analogs
Using the previously mentioned ITF assay, a library of linear peptides was tested
for direct binding potency by the Kontopidis lab (Table 2.1). In the preliminary biological
data, the native BRAF DIF sequence containing BRAF residues 503-521 (1) was tested in
cells and was shown to exhibit a dose-dependent inhibition of MEK/ERK phosphorylation.
This sequence when tested in the ITF assay was shown to have K d = 3.84 ±0.32 µM and
was therefore used as the baseline sequence for the experimental determination of the
peptidic binding determinants for the BRAF-wt dimer interface. Furthermore, a negative
control peptide containing the 3x mutation26 from Roering et al. in the BRAF 503-521
residue context (2) was tested and was determined to have no binding. In contrast,
another negative control peptide containing a scrambled sequence39 as reported by
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Freeman et al. in the BRAF 503-521 context (3) was tested in the ITF assay and
interestingly displayed a Kd = 2.96 ±0.18 µM, which is enhanced compared to the native
sequence. After assessing the BRAF-wt 503-521 native sequence (1) and the two negative
controls from literature sources (2 and 3), a library of linear peptides containing single
point mutations in the BRAF 503-521 sequence was generated and tested in the ITF assay
to experimentally explore the binding determinants of the DIF peptide.
Based on the crystal structure (PDB 4e26), L505 was not thought to contribute to
binding as evident by the L505A (4; 3.89 ±0.53 µM) showing binding equipotent peptide
1 (Table 2.1). Charge repulsion interactions between R506 and K507 were predicted to
electronically diminish the interaction of K507 with the DIF binding site. As expected, the
R506E (5; 1.09 ±0.29 µM) and R506L (6; 0.54 ±0.11 µM) peptides showed enhanced
binding owing to the elimination of the observed cation-cation repulsion of the Arg and
Lys side-chains. Substitution of T508, whose side-chain is in close proximity to the
opposite side of the reverse-turn and does not directly contact the binding surface, with
Asp (7; 2.20 ±0.83 µM) and Ala (8; 2.80 ±0.29 µM) exhibited a marginally enhanced
binding affinity. In contrast, the H510F (9; NB) substitution ablated binding of the peptide.
The V511A mutation (10; 4.75 ±1.7 µM) marginally decreased potency while L514A (11;
9.80 ±1.6 µM) more significantly hindered binding. Replacement of L515 with Ile (12; 4.10
±1.1 µM) slightly decreased potency while replacement with homoleucine (13; 1.25 ±0.36
µM) enhanced binding. The F516 side-chain was computationally determined to bind
above the protein R509 residue and mutation to Asp (14; NB) was predicted to enhance
binding through electrostatic interactions but experimentally demonstrated no binding.
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2.2.7 Truncation Study of BRAF DIF Peptides
The combined data from the crystal structure and the previously described
experimental data suggest that the entire BRAF 503-521 residue sequence is not required
for binding to the dimer interface. In this section, the truncation of the 503-521 sequence
was evaluated to minimize unnecessary residues from the DIF peptide sequence, all
experiments involving the ITF assay were carried out by the Kontopidis lab (Table 2.1).
Truncation to the 503-518 BRAF sequence (15; 1.88 ±0.36 µM) showed an enhanced
binding after elimination the YST sequence from the C-terminus. Removal of one residue
from either side in the further truncation to the 504-517 BRAF sequence (16; 5.75 ±1.2
µM) showed diminished binding. The addition of G518 (17; 0.13 ±0.04 µM) to the
sequence enhanced the binding potency with almost a 30-fold increase in binding
compared to the initial BRAF 503-521 sequence. Synthesis of the same BRAF 504-518
sequence with an amide C-terminus (18; 0.48 ±0.09 µM) resulted in diminished potency
compared to 17. Furthermore, acetylation of the BRAF 504-518 N-terminus (19; 0.80
±0.08 µM) showed an even further decrease in potency compared to the free amine.
From this data, the BRAF 504-518 sequence was determined to be the ideal scaffold for
further investigation into the binding determinants of the BRAF DIF peptides.
2.2.8 Alanine Scan of BRAF 504-518
Now that an optimum truncated sequence required for BRAF binding has been
identified, the individual contribution of each residue’s side-chain has been
experimentally evaluated using the same ITF assay as previously described. For this
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section, each of the residues were individually replaced with alanine as a method of
removing the functionality of the side-chain while the chirality of the residue was
maintained. From this experiment (Table 2.1), the results show that L505A (20; 0.45
±0.03 µM), R506A (21; 0.36 ±0.03 µM), F516A (28; 0.57 ±0.08 µM), and M517A (29; 0.54
±0.15 µM) are relatively insensitive to mutation. In contrast, K507A (22; ND), R509A (23;
2.4 ±0.35 µM), H510A (24; 2.7 ±0.40 µM), N512A (25; NB), and I513A (26; 2.69 ±0.35 µM),
and to a lesser degree L514A (27; 1.02 ±0.14 µM), had either diminished, very weak, or
no binding detected. Residues T508, V511, and L515 were excluded from this study since
the alanine mutation was already addressed for T508 and V511 in the BRAF 503-521
context and as L515 is known to bind to a deep, lipophilic pocket.
2.3 Discussion
There is a significant need for a combination therapy for patients with tumors
bearing the BRAF-V600E mutation to prevent the development of mutant RAS-driven
resistance mechanisms to Type I BRAF inhibitors. These RAS-driven tumors display an
enhanced proliferation while the patient is treated with Type I BRAF inhibitors due to
paradoxical activation of the second monomer in the wild-type BRAF dimer complex. The
proposed method of preventing this enhanced proliferation is through treatment with
BRAF-wt dimerization inhibitors. The initial data shows that co-treatment of human
melanoma SbCl2 cells, containing the NRAS-Q61K gain-of-function mutation, by
electroporation with Peptide 1 (BRAF DIF residues 503-521) and PLX 4032 (vemurafenib),
a Type I BRAF inhibitor, showed a dose-dependent decrease in phosphorylation of the
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downstream kinases, MEK and ERK (Figure 2.2) whereas treatment of these cells with PLX
4032 alone induced an enhanced ability to phosphorylate MEK/ERK compared to vehicle
alone.

This dose-dependent decrease in downstream substrate phosphorylation

indicates that DIF peptides can disrupt the dimerization of BRAF and inhibit tumorigenesis
under the disease-state conditions. Furthermore, cellular FAM-TAT-Peptide assays have
shown repeated diminishing phosphorylation of downstream kinases MEK/ERK, as well
as decreased transcription of FRA1, the transcription product of FOSL1, a transcription
factor activated by ERK (Figure 2.3C). Additionally, treatment with these peptides has
shown decreased cell viability of internalized, fluorescent peptides compared to negative
controls (Figure 2.3A/B).
Taken together, this data demonstrates on several accounts for the proof-ofconcept of use of BRAF DIF peptides to inhibit the phosphorylation of downstream
MEK/ERK, expression and phosphorylation of FRA1, and a decreased cell viability, all
under the paradoxical activation disease-state conditions. Furthermore, the comparison
between FAM-TAT-Pep17 and FAM-TAT-Pep6AlaNC3 demonstrates the requirement for
peptide side-chain functionality for residues which directly interact with the DIF binding
surface and therefore alludes that the binding potency can therefore be optimized.
Additionally, with the native conformation of the DIF sequence forming the reverse-βturn secondary structure, the potency, proteolytic stability, and cell penetrating ability of
the DIF peptide can further be enhance through cyclization to rigidify the structure and
lock it in the bioactive conformation. The development of BRAF-wt DIF peptides has the
potential to be used as a second-line therapy for patients with drug-induced resistance to
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Type I BRAF inhibitors as well as a potential therapy for patients exhibiting mutant RASdriven tumorigenesis.
Computational modeling of the linear DIF peptides using the crystal structure did
not prove to be quantitatively useful, but there was proof-of-concept for the binding of
peptides to BRAF-wt and disruption of downstream phosphorylation from the initial
biological data (Figure 2.2); DIF peptides of BRAF 503-521 including the native sequence
(1), 3x mutant reported by Roering et al. (2), and the scrambled peptide sequence
reported by Freeman et al. (3) were tested experimentally in the ITF direct binding
assay.26,39 As a baseline for this experiment, Peptide 1 exhibited Kd = 3.84 ±0.32 µM and
the 3x mutant (2) expectedly had no binding detected (Table 2.1). Interestingly, the
scrambled peptide analog (3), which was reported as a negative control in the activated
RAS and impaired activity in the BRAF-G466V context, exhibited a better binding than 1.
This retention of binding affinity could be due to the conservation of R509 and H510 in
the scrambled sequence which have been demonstrated to by key binding determinants
in the linear context, but the exact explanation for why the binding potency is enhanced
was not examined.
Next, a series of probing mutations to the BRAF 503-521 sequence and
subsequent ITF assay testing were completed (Table 2.1). L505 was determined to not
be required for DIF binding by the equipotent binding L505A (4) compared to 1. It was
speculated that the cationic sidechain of R506 energetically disfavored the binding of the
adjacent K507 residue to the DIF. Mutation of R506 to an anionic glutamic acid (5) or a
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lipophilic leucine (6) both significantly increased the binding potency by about 4-fold and
8-fold, respectively. T508 does not come into direct contact with the DIF binding surface,
but it is close in proximity to the other side of the reverse-β-turn. The testing of T508D
(7) and T508A (8) resulted in a marginally enhance binding, indicating that this residue is
relatively unaffected by mutation making it a prime residue for cyclization. Replacement
of H510 with a phenylalanine (9) resulted in the complete loss of binding, probably since
H510 is the central portion of the intramolecular hydrogen bond network with the
peptidic backbone amides which support the formation of the reverse-β-turn
conformation in the linear context. Without this network, the reverse turn in not
energetically favorable and due to an increased entropic cost of binding, the peptide loses
all binding ability. The substitution of alanine for V511 (10) and L514 (11) resulted in a
decreased binding potency, with the latter being more significant, though the decrease
in binding of L514A is difficult to explain since it does not contact the binding surface. As
probed in the molecular modeling, here too L515 and its deep hydrophobic pocket were
analyzed. Conversion of L515 to its isostere isoleucine (12) had a marginal hinderance
on binding, but substitution to homoleucine (13; 1.25µM) resulted in a 3-fold increase in
binding potency as expected by lengthening the alkyl side-chain and sterically filling the
deep, lipophilic binding pocket adjacent to the R509 binding pocket. F516 binds just
above the BRAF protein R509 in the minimized crystal structure and mutation to aspartic
acid (14) to mimic the negative dipole of the αC-helix was expected to increase binding
by interacting with the protein R509, but it resulted in no detectable binding. Taken
together, it was determined by this experimental set that there are energetically
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unfavorable adjacent residues with R506-K507, H510 is required in the linear peptide
context to maintain the bioactive conformation, and that the deep, lipophilic pocket of
L515 can be optimized to improve peptide binding.
After probing the BRAF 503-521 sequence with conservative mutations, it was
necessary to reduce the overall size of the linear peptide due to the fact that terminal
portions of the sequence do not directly contact the dimer interface and smaller
compounds are correlated with better oral availability. Size reduction which improves
drug likeness was accomplished by truncation to the core reverse-turn sequence which
directly binds to the BRAF DIF (Table 2.1). Truncation of the three C-terminal residues,
YST, resulted in 15, which is roughly a 2-fold increase in potency compared to 1. Further
truncation of one residue from each end resulted in 16 and about a 3-fold decrease in
binding potency. Upon reintegration of the N-terminal Gly gave 17 and a 14-fold increase
in potency compared to 15. Based on these observations, it is thought that the relative
length of the backbone in 17 and the proximity of the C-terminus to the R506 side-chain
created a psuedo-cyclic conformation of the linear peptide, making it energetically
favorable to preemptively assume the bioactive conformation.

The pseudo-cyclic

conformation thus decreases the entropic cost of binding and significantly increases the
direct binding potency. To test this theory, 18 was tested containing BRAF residues 504518 and an amide C-terminus. The resulting peptide exhibited a 4-fold decrease in
binding potency compared to its carboxylate counterpart. Since the C-terminus is an
amide instead of a carboxylate, there is no negative charge on the C-terminus thus
dampening its ability to assume the pseudo-cyclic conformation, but the amide nitrogen
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is still able to interact with the R506 side-chain, thus not completely eliminating the effect.
From the observations obtained from this experiment, it was decided to continue with
the truncated sequence containing BRAF residues 504-518 for the following experiments.
The alanine-scan in the computational model was lacking significant utility for the
design of more potent linear peptides, to better assess the contribution of each residue
an alanine-scan was performed on the linear BRAF sequence containing residues 504-518
with direct binding assessed by the ITF assay (Table 2.1). Residues L505, R506, F516, and
M517 were relatively insensitive to alanine mutation. In contrast, mutation of K507 and
N512 resulted in no detectable binding. K507 is expected to make an electrostatic
interaction with D448 in the protein binding site based on the crystal structure, the K507A
mutation was expected to hinder binding but not necessarily abolish it completely. In
regard to N512A, based on the crystal structure, the Asn side-chain makes hydrogen
bonds with the adjacent H510 which help to stabilize the reverse-β-turn in the linear
context, but again it was not expected to completely lose binding after mutation to
alanine. Furthermore, the mutation of R509 and H510 exhibited a diminished binding
potency as expected with R509 being a key binding determinant as reported by Roering
et al. and H510 composing the central participant in the hydrogen bond network
maintaining the reverse-β-turn in the linear peptide context.26 From the results, residues
507-515 (excluding T508) which make up the residues adjacent to the reverse-β-turn
appear to be highly sensitive to mutation and their side-chain functionality seems to be
important for potent binding in the linear peptidic context.
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2.4 Conclusion
Based on the biological application of the DIF peptides, either with or without the
FAM-TAT moiety, in the mutant RAS, BRAF wild-type context, co-treatment of cells with
type I kinase inhibitors and DIF peptides resulted in decreased downstream signaling.
Furthermore, treatment of cells in the same context showed a dose dependent decrease
in cell viability, thus inhibiting cell proliferation in the disease state context. This data in
addition to that previously described in Chapter 1 further indicates that the BRAF dimer
interface could be therapeutic target for treatment of patients with metastatic melanoma
which exhibit paradoxical activation-induced resistance to type I BRAF kinase inhibitors.
The direct binding assay results of probing mutations, truncation peptides, and
the alanine-scan of the core sequence were enlightening by determining the structure
activity relationship of residues in the linear context, such as which residues in the linear
context were crucial for binding and which were relatively insensitive to mutation or
elimination. From this data, it was confirmed that R509 is indeed a key residue for binding
of the linear peptide to the BRAF DIF as literature predicted.26 Furthermore, the
combination of the 503-518 truncation sequence and the core His-Val-Asn-Ile sequence
composing the predicted hydrogen bonding network of the reverse-β-turn may help to
stabilize the reverse-β-turn bioactive, pseudo-cyclic conformation and are therefore
appear to be crucial for binding in the linear context. Though these residues are
important for binding in the linear context, if the peptide was covalently cyclized then this
leaves room for additional optimization of reverse-turn residues for binding site affinity
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rather than stabilization of the predicted pseudo-cyclic conformation. Additionally, the
deep hydrophobic pocket which L515 binds can be exploited for optimization of binding
by elongating the aliphatic chain to fill this part of the dimer interface.
Taken together, this data supports our hypothesis of disrupting BRAF dimerization
with a peptide to prevent paradoxical activation induced by Type I BRAF inhibitors. It also
shows that there is room for optimization of the DIF peptides for the inhibition of
downstream phosphorylation events through cyclization, key binding determinant
optimization, as well as repurposing conformation stabilizing residues for binding affinity
optimization. Furthermore, residues which are relatively tolerant to mutation and do not
directly interact with the binding surface have been identified and present the
opportunity to optimize for physiochemical properties which make the peptide more
drug-like for cell permeability. In the next chapter, cyclization of the DIF peptides through
non-interacting residues is explored as a method of stabilizing the reverse-β-turn,
bioactive conformation via side-chain-to-side-chain cyclization methods which will in turn
result in a decrease in the entropic cost of binding and therefore lead to a more potent
DIF peptide.
2.5 Experimental
2.5.1 Peptide Synthesis
Linear peptides were synthesized and purified to greater than 95% purity by
GenScript.
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2.5.2 Electroporated Peptide 1 in SbCl2 cells in the presence of PLX4032 29
SbCl2 cells were electroporated with the BioRad GenePulser XCellTM in the
presence of the indicated concentrations of peptide 1. Following recovery at 37ᵒC for 30
min, the cells were treated with 1 µM PLX4032 for 1 hr. or dimethyl sulfoxide (DMSO) as
a

vehicle

control.

Subsequently, the

cells

were

harvested, lysed

using

radioimmunoprecipitation assay (RIPA) buffer, and analyzed by Western blotting using
the indicated antibodies, as described previously.26
2.5.3 FAM-TAT-Peptide Internalization29
Sbcl2 cells were plated in tissue culture vessels (6-well format) and grown in the
presence of the indicated concentrations of FAM-labeled TAT peptides. Medium with
freshly added peptides was changed every 3−4 days. Shown are micrographs taken 2
weeks after seeding.
2.5.4 FAM-TAT-Peptide Colony Forming Assay 29
Five thousand Sbcl2 cells were seeded onto 6-well plates and grown in the
presence of the indicated peptide concentrations for 2 weeks. Medium with freshly added
peptides was changed every 3−4 days. Cells were stained with Giemsa solution. Shown is
a representative result from two independent biological replicates with comparable
outcomes.
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2.5.5 FAM-TAT-Peptides in SbCl2 cells in the presence of PLX403229
NRAS Q61K mutant human Sbcl2 melanoma cells were incubated with 3.60 μM
FAM-TAT-pep6AlaNC3 (control) or FAM-TAT-pep17 for 3 days. Four hours prior to
harvest, the cells were treated with 1 μM vemurafenib (PLX4032) or the same volume of
DMSO as vehicle control. RIPA buffer lysates were subjected to Western blotting using
the indicated antibodies. Detection of HSP90 serves as a representative loading control.
2.5.6 Tissue Culture29
The generation of MCF-10Atet cells, a subline of the human mammary epithelial
cell line MCF-10A, was described previously.42 MCF-10Atet cells were grown at 37 °C in a
water-vapor saturated 5% CO2 atmosphere in conventional tissue culture plastic vessels
(Sarstedt, Nürnbrecht, Germany) containing Dulbecco’s modified Eagle medium/F12
medium (PAN-Biotech GmbH, Aidenbach, Germany) supplemented with 5 vol % horse
serum (PAA, Cölbe, Germany), 1 vol % glutamine (PAN-Biotech GmbH, Aidenbach,
Germany), 1 vol % HEPES (PAN-Biotech GmbH, Aidenbach, Germany), 1 vol %
penicilline/streptomycine (PANBiotech GmbH, Aidenbach, Germany), 250 μg of
hydrocortisone (Sigma-Aldrich, Munich, Germany), 50 μg of choleratoxin (Sigma- Aldrich,
Munich, Germany), 10 μg of human recombinant epidermal growth factor (R&D Systems,
Wiesbaden-Nordenstadt, Germany), and 4.858 mg of human recombinant insuline
(Actrapid Penfill solution, Novo Nordisk Pharma GmbH, Mainz, Germany). Cells were
passaged

twice

a

week

or

upon

reaching

confluency

and

detached

by

trypsin/ethylenediaminetetraacetic acid (EDTA) solution. Five hundred cells were plated
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onto 6-well plates and grown for 24 h prior to peptide treatment. For the experiments
with Sbcl2 cells, we used the stably transfected pool Sbcl2ecoR, which expresses the
receptor for murine retroviruses. These cells were cultivated as the parental cell line 43
and generated using the pQCXIN/ecoR plasmid, as described for other cell lines
previously.26
2.5.7 Western Blotting29
NRAS-Q61K-mutant SbCl2 melanoma cells were electroporated with BioRad
GenePulser XCell in presence of the indicated concentrations of peptide. Following
recovery at 37 °C for 30 min, cells were treated with 1 μM PLX4032 for 1 h with DMSO as
a vehicle control. Subsequently, the cells were harvested, lysed using RIPA buffer, and
analyzed by Western blotting using the indicated antibodies as described previously.26
Sbcl2 cells were lysed in RIPA buffer (50 mM Tris/HCl, pH 7.4; 1% Triton X-100; 137 mM
NaCl; 1% glycerin; 1 mM sodium orthovanadate; 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate, 0.5 mM EDTA; 0.01 μg/μL leupeptin, 0.1 μg/μL aprotinin, 1 mM AEBSF).
Lysates were cleared by centrifugation, mixed with the sample buffer, and analyzed by
Western blotting using 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis
gels, as described previously,26 using the following antibodies: anti-BRAF (F-7) and antiRAF-1 (C-12) purchased from Santa Cruz Biotechnology; anti-phospho-FRA1 (S265;
D22B1), anti- FRA1 (D80B4), anti-HSP90 (#4874), anti-phospho-MEK1/2 (pS217/221),
anti-MEK1/2, anti-p42/p44 MAPK, and anti-phospho-MAPK (pT202/pY204), and ERK1/2
purchased from Cell Signaling Technologies. Protein concentration determination was
performed via bicinchoninic acid assay (Thermo Fisher Scientific, Germany). Equal protein
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amounts were loaded for PAGE. Blotted proteins were visualized with a Fusion Solo
chemiluminescence reader (Vilber Lourmat, Germany).
2.5.8 Dissociation Constant (Kd) Determination from ITF and ITC Measurements 29
The dissociation constant is an indicator of the binding strength between two
molecules. For the reaction: P + L ↔ PL
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟏: 𝐾𝑑 =

[𝑃][𝐿]
[𝑃𝐿]

where [P] is the concentration of free Protein, [L] is the concentration of free Ligand, and
[PL] is the ligand-bound protein.
Fluorescence intensity was measured with a Hitachi F-2500 fluorescence
spectrophotometer. Briefly, 1.6 mL of protein solution (0.5 μM) was placed in a cuvette
and equilibrated at 15 °C for 1 h. After equilibration, small increments (2−15 μL) of the
ligand solution were injected in the cuvette. The ITF experiments were performed in 20
mM N-(2-hydroxyethyl)piperazine-N-ethanesulfonic acid (HEPES) buffer (pH 7.5), 10 mM
MgCl2, and 30 mM NaCl. For certain ligands that were insoluble in aqueous media, 5−10%
DMSO was added to increase its solubility. The slits were set at 10 nm for the excitation
and emission wavelengths. To determine the dilution effect of BRAF (due to ligand
addition) and any fluorescence effect by the unbound ligand, a blank sample containing
Trp with the same fluorescence signal was titrated with ligand additions, as described
above. The sample absorbance was kept below 0.1 to minimize the inner filter effect.44
The Kd of BRAF/ligand was calculated by fitting fluorescence data using the one-site
binding site model in Origin 7 as follows:
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2𝜃[𝑃𝑡𝑜𝑡𝑎𝑙 ]

𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟐: [𝐿𝑡𝑜𝑡𝑎𝑙 ] =

2
𝐾𝑏 (−𝐾𝑑𝑖𝑠𝑠 √𝐾𝑑𝑖𝑠𝑠
− 4𝐾𝑑𝑖𝑠𝑠 [𝑃𝑡𝑜𝑡𝑎𝑙 ](𝜃 − 1))
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+ 𝜃[𝑃𝑡𝑜𝑡𝑎𝑙 ]

TABLE 2.1: ITF DIRECT BINDING ASSAY DATA OF LINEAR BRAF DIF PEPTIDES
ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

BRAF
Residues
503-521
503-521
503-521
503-521
503-521
503-521
503-521
503-521
503-521
503-521
503-521
503-521
503-521
503-521
503-518
504-517
504-518
504-518
504-518
504-518
504-518
504-518
504-518
504-518
504-518
504-518
504-518
504-518
504-518

Mutations

Sequence

N/A
GVLRKTRHVNILLFMGYST
R509H, L515G, M517W GVLRKTHHVNILGFWGYST
Scrambled
GRINKGRHTFLLVVMTYSL
L505A
GVARKTRHVNILLFMGYST
R506E
GVLEKTRHVNILLFMGYST
R506L
GVLLKTRHVNILLFMGYST
T508D
GVLRKDRHVNILLFMGYST
T508A
GVLRKARHVNILLFMGYST
H510F
GVLRKTRFVNILLFMGYST
V511A
GVLRKTRHANILLFMGYST
L514A
GVLRKTRHVNIALFMGYST
L515I
GVLRKTRHVNILIFMGYST
L515homoleucine
GVLRKTRHVNIL[HL]FMGYST
F516D
GVLRKTRHVNILLDMGYST
N/A
GVLRKTRHVNILLFMG
N/A
VLRKTRHVNILLFM
N/A
VLRKTRHVNILLFMG
N/A
VLRKTRHVNILLFMG-NH2
N/A
Ac-VLRKTRHVNILLFMG
L505A
VARKTRHVNILLFMG
R506A
VLAKTRHVNILLFMG
K507A
VLRATRHVNILLFMG
R509A
VLRKTAHVNILLFMG
H510A
VLRKTRAVNILLFMG
N512A
VLRKTRHVAILLFMG
I513A
VLRKTRHVNALLFMG
L514A
VLRKTRHVNIALFMG
F516A
VLRKTRHVNILLAMG
M517A
VLRKTRHVNILLFAG
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Kd (µM)
3.84 ±0.32
NB
2.96 ±0.18
3.89 ±0.53
1.09 ±0.29
0.54 ±0.11
2.20 ±0.83
2.80 ±0.29
NB
4.75 ±1.70
9.80 ±1.60
4.10 ±1.10
1.25 ±0.36
NB
1.88 ±0.36
5.75 ±1.20
0.13 ±0.04
0.48 ±0.09
0.80 ±0.08
0.45 ±0.03
0.36 ±0.03
ND
2.40 ±0.35
2.70 ±0.40
NB
2.69 ±0.35
1.02 ±0.14
0.57 ±0.08
0.54 ±0.15

FIGURE 2.1: KEY DIF PEPTIDE BINDING MOTIFS: Minimized crystal
structures (PDB 4E26) of BRAF DIF peptides docked into BRAF dimer
interface, highlighting key residues for design of potent inhibitors. A.) The
chemical structure of protein and peptide R509 residues highlighted (grey)
in arginine-handshake motif. B.) L515 (cyan) highlighted to show deep
hydrophobic binding pocket. C.) Contribution of H510 (magenta) in
stabilization of the hydrogen bonding network which makes up the
reverse-β-turn of residues BRAF 510-514. D.) Hydrophobic residues V511,
F516, and M517 (green) shown to interact with the neutral binding
surfaces of the BRAF DIF.
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FIGURE 2.2: INHIBITION OF PARADOXICAL ACTIVATION WITH BRAF DIF
PEPTIDES: Treatment of metastatic melanoma cells SBcl2 under
paradoxical activation conditions with NRAS-Q61K and PLX4032
(vemurafenib) and electroporated with BRAF DIF peptides. Co-treatment
of cells with PLX4032 and BRAF DIF Peptide 1 exhibit a dose-dependent
decrease in downstream MEK/ERK phosphorylation compared to the
enhanced phosphorylation of MEK/ERK under paradoxical activation
conditions exhibited by PLX4032 treatment alone. Experiment was carried
out by the Brummer lab.
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FIGURE 2.3: FAM-TAT-PEPTIDES DIMINISH CELL VIABILITY AND INHIBIT DOWNSTREAM
TRANSCRIPTION: SbCl2 melanoma cells treated with FAM-TAT-Peptides, Pep17 and
Pep6AlaNC3 as the positive and negative samples respectively. A.) Confocal microscopy
of cells treated with FAM-TAT-Peptides indicating that 3.6 µM the fluorescent FAM label
is visible in the cells, whereas the 0.3 µM treatment merely shows a faint
autofluorescence. B.) Cell viability assay showing diminished cell viability in cells treated
with 1.8 µM FAM-TAT-Pep17 and a 4-fold increase in concentration is needed for FAMTAT-Pep6AlaNC3 to see the same effect. C.) Western blot of SbCl2 cells co-treated with
PLX4032 and FAM-TAT-tagged peptides to show down regulation of FRA1 expression as a
result of inhibiting BRAF and therefore the downstream products of ERK activation using
FAM-TAT-Pep17. Experiments were carried out by the Brummer lab.
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CHAPTER 3
OPTIMIZATION OF CYCLIC BRAF DIF PEPTIDES
3.1 Introduction
Until recently in drug discovery, small molecule inhibitors were the gold standard
for intercellular drug targets and mainly focused on out competing protein substrates
such as ATP and protein cofactors. With the exponential increase in cases of drug
resistance to small molecule cancer therapeutics, and as a way to expand the number of
available drug targets, attention has been turned to inhibiting protein-protein
interactions (PPIs) to disrupt signaling pathways. Macrocyclic peptides are defined as
compounds which are primarily composed of amino acid segments which form a ring
bridging several residues in the sequence. In recent years, the field of macrocyclic peptide
drug discovery has been increasingly pursued due to the ability of such molecules to bind
to large, flat, and featureless protein target surfaces of PPI interfaces. PPIs are generally
not amenable to small molecule development due to smaller surface area and
requirement for deep binding pockets for a therapeutic response.
Due to the biopolymeric nature of peptides, being composed of easily
interchangeable amino acids using straightforward synthetic strategies, large libraries can
be synthesized in an efficient manner making them advantageous for early stage
development of PPI inhibitors. Additionally, cyclization of peptide sequences allows for
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the compound to mimic the secondary structure of the target’s native substrate where
the conformational restraint decreases the entropic cost of binding and therefore
increases the peptide’s potency. Taken together, macrocyclic peptide drug discovery
involves straightforward synthetic means for development of compound libraries to
optimize potently binding sequences for inhibition of PPIs to which small molecule
inhibitors cannot efficiently bind.

A drawback of peptide drug discovery is the

fundamental lack of cell permeability of peptides which can be overcome using
macrocycles and will be addressed in detail in Chapter 4.
In the previous chapters, proof-of-concept for the application of a peptide as a
BRAF dimerization inhibitor for the prevention of PLX 4032-induced paradoxical activation
was demonstrated in cellular studies. Furthermore, in Chapter 2 the linear peptide
sequence was examined, and key binding determinants were identified as being the core
sequence surrounding the reverse-β-turn secondary structure of the BRAF protein dimer
interface (DIF). The contents of this chapter highlights the process of optimizing the lead
linear peptide (17) to create a macrocyclic peptide which potently binds the BRAF DIF.
3.2 Results
3.2.1 Design and Location of Peptide Cyclization Linker
From the previous linear truncation study, truncation of the BRAF 503-521
sequence to BRAF 504-518 significantly increased the potency of the peptide and was
attributed to the electrostatic interaction between the C-terminus of G518 and the sidechain of R506, creating a pseudo-cyclic conformation. This potential pseudo-cyclic
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conformation, along with the reverse-β-turn of the DIF from the crystal structure strongly
suggest that cyclization of the DIF peptides would greatly enhance binding ability by
rigidifying the peptide to the bioactive conformation, thus reducing the entropic cost of
binding. Residues 506 and 518 were therefore highlighted as a potential location for
introducing a cyclization linker and would result in a 13-residue macrocycle. The
minimized crystal structure (4e26) of the linear DIF peptide in the BRAF dimer interface
was examined for additional cyclization sites. The characteristics that were sought for
were the close proximity of two residues, with one on either side of the reverse-turn
moiety, and for the sidechain to not participate in direct binding to the DIF surface. Based
on these properties, two sites were chosen, side-chain cyclization between residues L505F516 or between T508-I513 (Figure 3.1). The first case would result in a 12-residue
macrocycle and the later in a 6-residue macrocycle.
3.2.1 Initial Cyclization Site Testing
All peptides were either cyclized using lactam cyclization linkers or disulfide
bridges between orthogonally protected residues during on-resin synthesis and the ITF
assay was carried out by the Kontopidis lab. The cyclization of BRAF residues 505-519
using cyclization residues 506 and 518 and either an 8 or 9 atom lactam linker resulted in
30 and 31 which were both insoluble and were not tested for binding (Table 3.1). When
BRAF residues 504-517 were cyclized through a disulfide bond at residues 505 and 516,
the resulting peptide (32) exhibited a Kd = 0.36 µM. Cyclization of BRAF residues 505-518
at residues 508 and 513 using an 8-atom linker (33) resulted in a Kd = 0.78 µM. Extension
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to a 9-atom linker resulted in 34 with Kd = 1.89 µM. When combining the 8-atom linker
with the N512A substitution, 35 was made and displayed a Kd = 0.46 µM. Incorporating
the N512A substitution into the 9-atom linker sequence resulted in 36 with Kd = 0.06 µM.
As proof-of-concept for the utility of the cyclization, 37 was tested with the same
sequence as 35, but without cyclization and the resulting peptide showed no binding to
BRAF DIF. Peptide 38 was made as a trial for the idea of a bicyclic peptide by cyclizing
through the 505-516 site and the 508-513 site using two lactam cyclization linkers and
resulted in Kd = 0.37 µM.
3.2.2 Cyclic Peptides Show Decreased Entropic Cost of Binding
As a method of confirming the results from the ITF assay and to explore the
thermodynamics of BRAF DIF peptides binding, isothermal titration calorimetry
experiments performed by the Kontopidis lab were completed for a few select peptides.
Testing of the 19-residue linear peptide 7 (Figure 3.2) resulted in a moderate difference
in binding affinity (Kd = 14.9 ± 10.8 μM; ΔH = −34.8 kJ/mol; ΔS = −28.4 J/(mol K)) compared to
that observed in the ITF assay (Kd = 2.20 ±0.83 μM), though the error was larger for ITC. The
binding data of the 15-residue peptide 17 had a similar binding affinity (Kd = 0.35 ± 0.17 μM; ΔH
= −199 kJ/mol; ΔS = −567 J/(mol K)) to that determined by the ITF assay (Kd = 0.13 ± 0.04 μM).
Furthermore, it appeared that both linear peptides were enthalpically driven to bind based on
their favorable ΔH and their unfavorable ΔS terms. The cyclic peptide 35 was confirmed to also
have a similar binding potency in the ITC experiment (Kd = 0.31 ± 0.16 μM; ΔH = −9.41 kJ/mol;
ΔS = 92.05 J/(mol K)) compared to that of the ITF assay (Kd = 0.46 ± 0.04 μM). Furthermore, this
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peptide appeared to be entropically driven to bind, which is in line with the rationale of creating
the cyclic peptide, based on the favorable value of the ΔS term determined by ITC.

3.2.3 Probing and Truncation of 508-513 Cyclized Peptides
In the previous section, substitution of N512 for alanine showed an enhanced
binding effect in the context of the 508-513 cyclized peptide (36). In this section, the 6residue cyclic peptide is further examined for enhanced binding opportunities when
tested in the ITF assay by the Kontopidis lab (Table 3.1). In Chapter 2, L515 was described
as a prospect for enhanced binding due to the lipophilic binding pocket. A peptide
containing a 6-residue macrocycle with an 8-atom linker, the N512A mutation, and L515
is substituted for homoleucine, resulted in peptide (39) and exhibited a Kd = 0.43 µM. In
the same scaffold, when L515 is substituted for Nle (norleucine), the resulting peptide
(40) has an enhanced Kd = 0.17 µM. In the 9-atom cyclized peptide (508-513), reducing
the number of hydrogen bond donors through N-methylation of R509 to make 41 resulted
in Kd = 0.39 µM, of which binding is slightly diminished compared to the non-methylated
counterpart but reduction of HBDs aids in passive cell permeability. Truncation of the 9atom linker construct from the N-terminus gives peptide 42 with Kd = 0.59 µM. With the
addition of the V511P mutation (43) to stabilize the reverse-β-turn with the rigid, cyclic
proline residue, potency was enhanced 3-fold (Kd = 0.19 µM). Further truncation of the
C-terminus of the 42 sequence to make 44 resulted in Kd = 0.30 µM.
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3.3 Discussion
The key binding determinants of the linear DIF peptide have been examined using
computational modeling as well as an experimental direct binding assay. From that data,
there is evidence of enhanced binding through maintaining the bioactive conformation of
the native BRAF protein. For example, mutating either H510 or N512 resulted in either
diminished binding or no binding detected in the linear context (Table 2.1). This is
thought to be due to these residue’s role in the intramolecular hydrogen bonding network
which supports the stability of the bioactive conformation. Furthermore, truncation of
the sequence to BRAF residues 504-518 (17) resulted in a 30-fold increase in potency
compared to Peptide 1 (Table 2.1), this is suspected to result from a pseudo-cyclic
conformation emerging from the electrostatic interaction between the C-terminus and
side-chain of R506. This section aims to examine the implications of covalently cyclizing
the peptide sequence to allow for enhanced binding to the BRAF DIF.
The first aspect of peptide cyclization which was examined was the location
(Figure 3.1) and type of cyclization linker used. First it was decided that the method of
cyclization would be through using orthogonally protected acid and amine residues to
create a lactam cyclization linker once deprotected, this method was used for most of the
cyclic peptides. Then the location needed to be determined, drawing inspiration from the
pseudo-cyclic linear peptide (17) and from the conformation of the truncated DIF in the
reverse-β-turn secondary structure in the crystal structure, the BRAF sequence 505-519
was cyclized by a lactam linker through residues 506 and 518. There were two peptides
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made using either an 8-atom or 9-atom linker, 30 and 31 respectively, unfortunately, both
peptides were insoluble and were not tested. Peptide 32 was cyclized through the side
chains of residues 505 and 516 due to their proximity (Figure 3.1) and their lack of direct
binding to the DIF surface. This peptide was a 12-residue macrocycle with side-chain
cyclization through a disulfide bridge (32; Table 3.1) and was slightly less potent than the
pseudo-cyclic linear peptide 17 (Table 2.1), but more importantly, this peptide had a 15fold greater affinity compared to its linear counterpart peptide 16 thus supporting the
rationale of cyclization. Furthermore, considering the overall goal of this project, a large
macrocycle such as this one may have issues when it comes to drug-likeness. With trying
to make the most potent and smallest cyclic peptide as possible, peptide 33 was made by
cyclizing the peptide at residues 508 and 513 to make a 6-residue macrocycle. This
peptide was cyclized using an 8-atom lactam linker and exhibited a decreased binding
affinity compared to 32 but the core macrocycle was smaller giving it more potential for
drug-likeness optimization. While trying to improve the linker length, 34 was made with
a 9-atom lactam linker and resulted in diminished binding compared to the 8-atom linker
counterpart, which is even further reduced compared to the pseudo-cyclic linear peptide
(17). Furthermore, 6-residue macrocycles were made using both lactam linkers and
replacing N512 with alanine due to the lack of need for the hydrogen bonding network in
the cyclic context. Interestingly, 35 with the 8-atom linker had equipotent binding as 32
and was improved over the original native sequence. Peptide 36 with the 9-atom linker
exhibited an increase in potency and is 6-fold more potent than the disulfide cyclized 32.
Overall, two peptide cyclization sites were discovered (505-516 and 508-513) and have
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shown proof of concept for the utility of cyclizing the peptide to stabilize the reverse-turn
bioactive conformation for enhanced affinity.
As a proof-of-concept for the validity of peptide cyclization, the 35 sequence was
made in the linear context (37) and resulted in no binding to the BRAF DIF (Table 3.1),
thus demonstrating that cyclization is significantly benefiting the DIF-peptide interaction.
To further investigate the cyclization of the DIF peptide sequence, a bicyclic peptide (38)
was made where the inner macrocycle was connected by a 9-atom lactam linkage at the
508-513 site, and the outer macrocycle was connected by a 5-atom lactam linkage at the
505-516 site. The resulting peptide exhibited equipotent binding as the large macrocycle
alone in peptide 32. Based on these results, it seems that the optimum fit for the
cyclization of BRAF residues 505-518 were through the 508-513 site using a 9-atom lactam
linker creating a 6-residue macrocycle which strictly encompasses the reverse-turn motif
and can further be enhanced through sequence optimization now that the reverse-turn
residues are no longer required for secondary structure stabilization.
A few different mutations were explored in the cyclic context of the DIF peptide.
Using the 508-513 cyclized peptide with the 8-atom linker, the mutation of L515 was
explored by mutation to homoleucine (hL) and norleucine to sterically fill the deep
lipophilic binding pocket. In the first case, 39 exhibited an equipotent binding coefficient
to the original sequence (Table 3.1), whereas the norleucine substitution resulted in 40
with enhanced binding affinity by 2-fold when compared to 35. This is interesting because
in the linear 503-521 context, the L515hL mutation (13) gave a 2-fold increase in potency,
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but now in the cyclic context the mutation does not benefit the binding. Additionally, in
the peptide 36 context, the N-methylation of the backbone amide of R509 (41), for cell
permeability enhancement by decreasing the overall number of hydrogen bond donors,
resulted in a 6-fold decrease in binding affinity. Based on interactions in the crystal
structure, the decreased affinity cannot be explained since the NH does not play a direct
role in binding to the BRAF DIF. Furthermore, the αNH bond of R509 points to the exterior
of the macrocycle, disputing its role in intramolecular hydrogen bonding. Additional
alterations of the sequence of 36 include truncation of the exocyclic C-terminus, residues
505-507, resulting in a 10-fold drop in potency (42). This peptide, though it did lose a
relatively significant affinity, it also demonstrated that the exocyclic C-terminus retained
respectable activity. Furthermore, the residue V511 was mutated to proline since it could
potentially stabilize the reverse turn. Testing of 43 indicated a 3-fold increase in binding
compared to 42, demonstrating that the initial drop in potency of 42 can be recovered by
sequence optimization and confirming that stabilization of the reverse-β-turn is
important even in the cyclic context. In a further truncation study, exclusion of both the
exocyclic C-/N-terminus to generate 44 resulted in a 2-fold increase compared to just the
C-terminus truncation alone (42), additionally this peptide is equipotent to the larger
macrocycle (32) and more potent than the much longer linear peptides, demonstrating
the optimum conformation of this small macrocycle with fewer points of contact.
Interestingly, this peptide excludes the L515 hydrophobic interaction which was thought
to be crucial in the linear context but perhaps plays a lesser role in the cyclic form. It is
also possible that incorporation of the exo-cyclic C-terminus reduces the overall flexibility
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of the bound macrocycle, thus hindering the binding conformation. Taken together, it
appears that optimization of L515 binding could be beneficial to binding in the cyclic
context may not be necessary based on the truncation study. Furthermore, it appears
that the exocyclic truncation of the peptide results in retained binding, thus reducing the
overall size and increasing the drug-likeness of the peptide, and through sequence
optimization of the truncated cyclic peptide 44, potency can be recovered while
maintaining a smaller, more drug-like macrocycle.
3.3 Conclusion
The rationale for developing potent BRAF inhibitors was to take advantage of the
reverse-β-turn in the DIF sequence in order to develop a cyclic peptide which binds the
BRAF dimerization interface with high affinity. Optimization of the cyclization method for
the peptide has resulted in cyclization through the side chains of residues 508 and 513
and a 9-atom lactam linker. The ITF and ITC experiments have provided experimental
proof of concept for the benefit of cyclization by decreasing the entropic cost of binding
in cyclic peptides. This concept is exemplified by the comparison of 16 and 32 where
cyclization produced a 15-fold increase in binding affinity as well as in the comparison of
37 and 35 where the cyclic 35 displayed enhanced affinity and the linear counterpart
produced no binding. Overall, optimization has achieved 36 which has 64-fold more
binding affinity for the BRAF DIF than peptide 1. Furthermore, it appears that the cyclic
sequence can be improved further by optimization of the L515 residue for deep binding
into a hydrophobic pocket and the V511P substitution can be used to further stabilize the
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reverse-turn, rescuing the diminished binding from exocyclic truncation. Additionally,
truncation of the exocyclic peptide sequence has yielded a small macrocycle which
maintains relatively high affinity at a third of the DIF contact area, thus making the
peptide more drug-like and a prime scaffold for design of BRAF DIF inhibitors.
3.4 Experimental
3.4.1 Standard Fmoc Chemistry Solid Phase Peptide Synthesis Protocol
The linear peptide sequence was synthesized on a solid support resin, usually Rink
Amide ChemMatrix resin, using Nα-Fmoc protected amino acids with acid-labile sidechain

protecting

groups,

1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-

b]pyridinium 3-oxid hexafluorophosphate (HATU) as the coupling reagent, and
diisopropylethylamine (DIPEA) as the base. Resin was allowed to swell in DMF for 30 min
with shaking. For resin loading, the first amino acid (2 eq), HATU (2 eq), and DIPEA (4 eq)
were dissolved in DMF, added to the resin, and allowed to shake for 4 hours. Following
the reaction, the vessel was drained and the addition was repeated once more. After
coupling of the first residue, the resin was drained, rinsed three times each with DMF,
DCM, and DMF again, and then the resin was tested for primary amines using the Kaiser
test. The resin was then Fmoc deprotected by treatment with piperidine (20% in DMF)
two times 10 min. The resin was then drained, washed, and again Kaiser tested. The
process was then repeated with the next residue, using 2 hour coupling times, in the
sequence until the intended peptide sequence was complete.
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3.4.2 Kaiser Test Protocol45
A small portion of the resin beads were added to a test tube, to which three drops
each of the Kaiser test solutions (as described by the AAPPTec Kaiser Test recipe) were
added and the solution was heated at 100°C in an oil bath for 5 min. The solution was
then removed from heat, the solution was decanted, and the beads were washed once
with ethanol. The color of the beads indicates whether there are free amines on the resin;
clear beads indicate that there are no free amines and blue or purple beads indicate that
there are free amines.
3.4.3 Solid Phase Peptide Synthesis of Cyclic Peptides
The linear sequence of peptides were synthesized using standard Fmoc chemistry
as described in Section 3.4.1. Coupling reactions were completed by treatment with the
Fmoc-Nα-amino acid, HATU, and DIPEA 2x 2 hours and Fmoc deprotection reactions were
completed by treatment with piperidine (20% in DMF) 2x 10 min (the final residue was
left Fmoc-protected). After the linear synthesis of the intended sequence, orthogonally
protected cyclization residues (Alloc and Allyl protecting groups) were deprotected by
treatment with tetrakis(triphenylphosphine)palladium (cat.) and phenylsilane (100 µL)
dissolved in DCM 4x 5 min. The resin was then washed ten times with DCM to remove all
catalyst. The peptide was then cyclized by treatment with HATU (4 eq) and DIPEA (8 eq)
dissolved in DMF overnight. The resin was then washed three times each with DMF, DCM,
and DMF again, and the final residue was Fmoc deprotected as previously described. The
peptide was then cleaved from the resin by treatment with a solution of TFA/TIPS/H 2O
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(94/5/1) for 2-4 hours. The solution was then collected along with a TFA rinse, and the
sample was dried via evaporation at reduced pressure.
3.4.4 Purification of Synthetic Cyclic Peptides
After cleavage from the resin, peptides were concentrated to a minimal volume
of trifluoroacetic acid (TFA) and were placed on ice. The peptide was then precipitated
with cold diethyl ether (~5 mL) and were spun down using a centrifuge and the solution
was decanted. The remaining solid was dissolved in DMSO and the peptide was purified
via semi-preparative LCMS using the Phenomenex Luna 5u C18(2) 100Å column which
was 250x10.00 mm with a 5 micron pore size. Peptides were separated using a
water/acetonitrile/0.1% formic acid mobile phase on a 5-40%B over 40 min gradient. The
sample was obtained through mass-based collection methods.

Fractions were re-

analyzed by analytical LCMS to determine pure fractions, which were then combined,
rotovapped to remove the organic solvent, lyophilized, and weighed.
3.4.5 Intrinsic Tryptophan Fluorescence (ITF) Assay29
See section 2.5.8.
3.4.5 Isothermal Titration Calorimetry (ITC)29
ITC was measured with an Affinity ITC instrument (190 μL cell volume, TA
Instruments, USA) at 15 °C with stirring speed 170 rpm. The ITC experiments were
performed in 20 mM N-(2-hydroxyethyl)piperazine-N-ethanesulfonic acid (HEPES) buffer
(pH 7.5), 10 mM MgCl2, and 30 mM NaCl. For certain ligands that were insoluble in
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aqueous media, 5−10% DMSO was added to increase its solubility.The sample cell was
loaded with the solution of 6.5−10 μM of protein and the 50−1000 μM peptide inhibitor
solution was placed in the injection syringe. In a typical experiment, 12 injections of 2 μL
aliquots of the peptide were added into the calorimeter cell. Data analysis was performed
using NanoAnalyze software according to model of the single set of identical independent
sites. Also two “blank” experiments were performed with the above settings.
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TABLE 3.1: ITF DIRECT BINDING ASSAY DATA OF CYCLIC BRAF DIF PEPTIDES

ID
30
31
32
33
34
35
36

BRAF
Residues
505-519
(c506-518)
505-519
(c506-518)
504-517
(c505-516)
505-518
(c508-513)
505-518
(c508-513)
505-518
(c508-513)
505-518
(c508-513)

37

505-518

38

504-518
(c505-516)
(c508-513)

39

505-518
(c508-513)

40
41
42
43
44

505-518
(c508-513)
505-518
(c508-513)
508-518
(c508-513)
508-518
(c508-513)
508-513
(c508-513)

Mutations

Sequence

Kd (µM)

R506K, G518E

LKKTRHVNILLFMEY

INS

R506O, G518E

LOKTRHNVILLFMEY

INS

L505C, F516C

VCRKTRHVNILLCM

0.36 ±0.32

T508O, I513E

LRKORHVNELLFMG

0.78 ±0.01

T508K, I513E

LRKKRHVNELLFMG

1.89 ±0.33

T508O, N512A,
I513E

LRKORHVAELLFMG

0.46 ±0.04

T508K,N512A, I513E

LRKKRHVAELLFMG

0.06 ±0.01

LRKORHVAELLFMG

NB

V-Dab-RKKRHVAELLDMG

0.37 ±0.03

LRKORHVAEL-hL-FMG

0.43 ±0.03

LRKORHVAEL-Nle-FMG

0.17 ±0.06

LRKK-MeR-HVAELLFMG

0.39 ±0.02

T508K,N512A, I513E

KRHVAELLFMG

0.59 ±0.02

T508K, V511P,
N512A, I513E

KRHPAELLFMG

0.16 ±0.02

T508K,N512A, I513E

KRHVAE

0.30 ±0.03

T508O, N512A,
I513E
L505Dab, T508K,
N512A, I513E,
F516D
T508O, N512A,
I513E,
L515homoleucine
T508O, N512A,
I513E, L515Nle
T508K, R509MeR,
I513E
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TABLE 3.2: ITC THERMODYNAMICS DATA

ITF
ITC
ΔH
ΔS
Kd (µM) Kd (µM) (kJ/mol) (J/(mol K))
Pub #8 GVLRKARHVNILLFMGYST
2.80 14.9 ±10.8 -34.8
-28.4
11
VLRKTRHVNILLFMG
0.13 0.35 ±0.17 -199.0
-567.0
31
LRKORHVAELLFMG
0.46 0.31 ±0.16
-9.4
92.1

Peptide

Sequence
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FIGURE 3.1: BRAF DIF PEPTIDE CYCLIZATION SITES: Shown above is the truncated DIF
peptide (residues 504-518) with two cyclization sites. Site 1 makes a larger 12 residue
macrocycle between L505 and F516 (yellow) and site 2 makes a 6 residue macrocycle
between T508 and I513 (green), R519 is shown in magenta for perspective.
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FIGURE 3.2: ITC DATA FOR LINEAR AND CYCLIC PEPTIDES
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CHAPTER 4
OPTIMIZATION OF PHYSIOCHEMICAL PROPERTIES OF CYCLIC BRAF DIF PEPTIDES FOR
PASSIVE CELL PERMEABILITY
4.1 Introduction
4.1.1 The Growing Need for Drug Space Beyond Small Molecule Therapeutics
Drugs are designed to be taken by patients in order to cause a physiological effect
which is therapeutic in nature. Most medications are administered to the patient orally
which means that the drug must be able to be absorbed through the gastrointestinal tract
and travel through the body to the therapeutic target.

In the context of cancer

therapeutics, most of the drug targets are located within the cells of the tumor, and
therefore the drug must be able to pass through the phospholipid bilayer of the cell
membrane in order to reach its target to cause a therapeutic effect.
Due to their favorable absorption, small molecules such as Type I kinase inhibitors
continue to be used as therapeutic tools to invoke a physiological response by outcompeting adenosine triphosphate (ATP) or other co-factors to inhibit oncogenic proteins
for the treatment of cancer. With the growing need for second-line therapies for drug
resistant malignancies, novel therapeutic targets are needed for efficacious treatment of
advanced stage cancers which inhibit oncogenic targets potently and selectively.
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In recent years, therapeutically targeting protein-protein interactions (PPIs) has
become a growing field in drug discovery as a method of inhibiting the interaction of
oncogenic proteins with either upstream effectors or downstream substrates. This
method of inhibition allows for the design of compounds which are selective for the target
protein’s binding surface rather than the ATP ligand pocket which is relatively conserved
across the kinase families, though inhibiting PPIs can be utilized for other protein families
as well. A hindrance to the development of PPI inhibitors is that binding interfaces tend
to be quite large, flat, and featureless and therefore requiring the need for larger
compounds to block these interactions. The development of larger and more complex
compounds as therapeutics fundamentally violates the guidelines oral availability which
were originally established by Lipinski et al. and later revised by Veber et al. owing to the
idea that with increased size there will be an increase in polarity which will inhibit
compounds from crossing the lipophilic membrane passively (Table 4.1), thus
complicating the situation with the question, how can larger compounds, greater than
500 Da, enter the cell to inhibit these protein-protein interactions in a therapeutic
manner?
4.1.2 Hallmarks of Cell Permeability
In the field of drug design, Lipinski’s Rule of Five (Ro5) was previously regarded as
the gold standard for design of small molecule drugs which are orally available. This rule
came from Christopher Lipinski’s publication in 1997 which was written in the Advanced
Drug Delivery Reviews journal outlining the chemical properties which a substance should
have in order to be orally bioavailable.46 The rule states that the compound should have
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a molecular weight less than 500 Da, less than 5 hydrogen bond donors, less than 10
hydrogen bond acceptors, and a water-octanol partition coefficient less than 5 (Table
4.1).
Later, in 2002, a paper by Veber et al. was published in the Journal of Medicinal
Chemistry which took another look at the requirement of a compound for cell
permeability.47 Veber et al. stated that the better molecular properties for the prediction
of oral availability were the number of rotatable bonds as a measurement of molecular
flexibility and the polar surface area (defined as the sum of hydrogen bond donors and
acceptors) of the compound. The article also stated that the molecular weight does not
impede cell permeability, but in a general sense, with increased molecular weight there
is an increased number of rotatable bonds and polar surface area which determines cell
permeability. In this article, the oral bioavailability of 1100 drug candidates were
analyzed in rats and it was determined that having fewer than 10 rotatable bonds and a
polar surface area of less than 140 Å2 (less than 12 total hydrogen bond acceptors and
donors) was an effective predictor of cell permeability independently of molecular weight
(Table 4.1).
With the growing enthusiasm of targeting protein-protein interactions, there is
also an enhanced need to explore the drug space beyond the realm of small molecule
drugs. In recent years there has been several articles which have extensively screened
large libraries of macrocyclic compounds for their ability to be cell permeable even
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though they have molecular weights which exceed the restraint defined in Lipinski’s rule
of five.48–50
4.1.3 Cell Permeability of Macrocyclic Peptides
With the intent to inhibit protein-protein interactions, it is likely that larger
compounds with a broad binding surface will be needed to bind the large, flat, and rather
featureless surfaces of one of the partners and compete with the other for binding. Since
the ligand of PPI binding sites are other proteins, generation of peptide libraries has
grown in popularity as screening methods for PPI inhibitor hit or partial hit discovery.
Partial hits can then be combined with post-synthesis modifications which can enhance
binding if the ligand sequence is not contiguous for the PPI interaction.51–54 While
optimization of binding using peptidic sequences as potential drug leads sounds
advantageous, peptides in themselves have several drawbacks to being used as drugs
including fast clearance, low proteolytic stability, and low cell permeability which
negatively affects their therapeutic utility as drugs.48,50,55 The following section will focus
on examples of cyclic peptides which have the ability to permeate the cell as well as the
modifications which can be used to promote cell permeability of designer peptides for
therapeutic applications.
A recent review states that there are several methods for to improve cell
permeability through passive diffusion, active transport, direct translocation or
endocytosis.56 Passive diffusion (PD) is energy-independent and the main mechanism by
which small molecule therapeutics gain entry into a cell and for which the Ro5 defines
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acceptable physicochemical parameters . PD is possible where the lipophilicity of the
compound enables desolvation to enter the membrane and then resolvation to exit into
the cytosol in an energy efficient manner. Active transport (AT) involves the energydependent uptake of drugs and takes advantage of integral transporter proteins whose
key role is to transport nutrients and metabolites into the cell. AT can also involve solute
carrier proteins (SLC) known to transport a variety of different compounds into the cell.
Direct translocation is another mechanism poorly defined and where at high
concentrations, peptides can directly transverse the membrane directly into the cytosol.
Cell penetration of peptides can also occur through endocytosis of positively charged
peptides followed by endosomal escape into the cytosol. Here we focus on the passive
diffusion of cell permeability of cyclic peptides as the main route of cellular entry.
The fundamental issue hindering passive diffusion of peptides across the cell
membrane is their high polarity. They typically have a large number of hydrogen bond
donor (HBD) and hydrogen bond acceptors (HBA) giving a large overall polar surface area
(PSA), an unfavorable characteristic to allow passage through the hydrophobic conditions
inside the membrane phospholipid bilayer. In particular, the polarity contributed by the
HBDs/HBAs of the amide backbone contributes to the energy required to desolvate the
amide groups during the transition from the aqueous to the lipophilic environment as
established by Burton et al.57 Masking the HBDs of the amide backbone is therefore an
effective approach for promoting cell permeability of peptides and methods of doing this
include N-methylation of amide nitrogens, incorporation of bulky aliphatic groups as
amino acid sidechains, increased frequency of proline residues, and incorporation of
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peptoid functionalization. All of these methods will either replace the amide proton and
decrease the PSA or sterically hinder the formation of hydrogen bonds between the
amide proton and the aqueous environment, thus decreasing the desolvation energy
required for the peptide to enter the lipophilic environment of the cell membrane.
A classic example of a cyclic peptide which is cell permeable is Cyclosporine A
(CsA), an immunosuppressive drug which can be taken orally and is used to prevent organ
transplant rejection as well as treat rheumatoid arthritis and psoriasis. Cyclosporin A is a
head-to-tail cyclized peptide which is 11 residues in length and is made up of mainly
natural, hydrophobic, aliphatic residues. The key structural features of CsA leading to to
its cell permeability is the pattern of N-methylation of the amide backbone and the
intramolecular hydrogen bond network which occurs upon introduction of the peptide to
a hydrophobic environment. In a study analyzing the contribution of cyclization for the
cell permeability of CsA, a 10-residue cyclic analog, and the acyclic precursor was
studied.53,58 Of these samples the truncated analog and the linear analog were isolipophilic based on the experimental polar surface area and had the ability to form the
same intramolecular hydrogen bond network. Based on the RRCK values representing
cell permeability rates, the acyclic peptide was 20-fold less permeable than its cyclic
counterpart. This decrease in permeability was attributed to the linear analog occupying
significantly greater conformational space than the cyclic analog. This study showed that
there is more that dictates the cell permeability of peptides than just the physiochemical
properties, and that restricting the peptide to the cyclized conformation decreased the
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entropic cost of energy for desolvation of the peptide to form the intramolecular
hydrogen bond network required for passive diffusion.
A recent review by Nielsen et al. recognized the need for peptide cyclization as a
way of orienting the sidechains of the peptide in a manner to shield the polar functional
groups for cell permeability.50 Nielsen et al. analyzed the physiochemical properties
associated with cell permeability of 125 cyclic peptides with reported bioavailability in
order to probe the chemical space beyond the rule of five (bRo5). From this study, they
found that the limit on molecular weight (MW) can be increased in this context with
reported bioavailability from peptides with MW of 500-1350 Da. As for the number of
hydrogen bond donors (HBDs), this property is roughly consistent with the Ro5 with cyclic
peptides exhibiting bioavailability with HBDs of 1-6. In the case of hydrogen bond
acceptors (HBAs) and water-octanol partition coefficient (LogP), bioavailable peptides
were seen with HBA ranging from 5-20 and LogP of 1-8, which extends the Ro5 (Table
4.1). Furthermore, comparing with Veber’s extension to the rule, peptides containing 520 rotatable bonds and a topological polar surface area of < 300 Å2 were seen to have
ample bioavailability, almost doubling the acceptable tPSA and number of rotatable
bonds. Thus, there is more to be considered than the original Ro5 parameters when
trying to predict cell permeability of cyclic peptides.
4.1.4 Peptide to Peptidomimetic REPLACEment
REPLACE (Replacement with Partial Ligand Alternatives through Computational
Enrichment) is a validated strategy for conversion of peptides to drug-like compounds
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which inhibit protein-protein interactions (PPIs).59–61 The REPLACE strategy iteratively
substitutes peptide segments for small molecule fragments deemed favorable through
the use of computational methodology as a platform for broadening the landscape of PPI
inhibitor technology (Figure 4.1). In a sense, the structure activity relationship is initially
optimized through the generation of peptide libraries which are screened for direct
binding affinity. A peptidic sequence is then truncated and Partial Ligand Alternatives
(PLAs) are docked into the binding site using computational methods, replacing the initial
segment. High scoring PLAs are then synthetically ligated to the truncated peptide to
generate FLIPs (Fragment Ligated Inhibitory Peptides) which are then tested for binding
efficiency. PLAs which are highly active and recapitulate the affinity of the native peptide
in the FLIP context are kept and the process is repeated with the next peptidic segment
until the entire peptide is converted to a drug-like compound with optimized binding. The
iterative conversion of the sequence to a can enhance the binding affinity and cell
permeability, thus resulting in a more drug-like compound.
4.2 Results
4.2.1 Passive Cell Permeability of BRAF DIF Peptides
The peptide library was gradually optimized include physiochemical properties
which might promote passive cell permeability based on the bRo5 guidelines for cell
permeable cyclic peptides (Table 4.1).50 Peptide 1 consisted of BRAF residues 503-521
(Kd = 3.84 µM) and had a MW of 2205.66 g/mol, 28 hydrogen bond donors, 26 hydrogen
bond acceptors, and a topological polar surface area of 885 Å2 (Table 4.2). Truncation to
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residues 505-518 and optimized cyclization (36; Kd = 0.06 µM) resulted in a dramatic
increase in potency and an overall decrease in size (MW = 1679.12 g/mol; HBD = 20; HBA
= 18; cLogP = -3.78; tPSA = 651 Å2). Truncation of exocyclic sequences after cyclization
(44; Kd = 0.30 µM) resulted in a compound with good affinity while decreasing its size,
the number of HBD/HBAs, and its topological polar surface area (MW = 719.85 g/mol;
HBD = 10; HBA = 9; cLogP = -3.94; tPSA = 330 Å2), however with a similar cLogP. The
REPLACE strategy was used to design exocyclic capping groups more druglike in nature
(53) and largely within bRo5 guideline ranges (MW = 1014.24 g/mol; HBD = 10; HBA = 11;
cLogP = 1.94; tPSA = 328 Å2). Further optimization of the macrocyclic sequence resulted
in a lead peptide in terms of affinity (54; Kd = 0.017 µM) while meeting all bRo5 criteria
except the number of HBD (MW = 960.19 g/mol; HBD = 7; HBA = 10; cLogP = 3.13; tPSA =
286). Further optimization of the cyclic sequence for cell permeability was attempted by
replacement of the “aPA” sequence in 54 with an alkyl chain to generate a compound
meeting all of the bRo5 guidelines (MW = 862.13 g/mol; HBD = 6; HBA = 7; cLogP = 3.71;
tPSA = 237 Å2).
4.2.2 Temperature Coefficient NMR Study of BRAF DIF Peptides
One of the leading theories explaining the cell permeability of cyclic peptides
involves the chameleon effect which the peptide structure allows for dynamic conversion
of cyclic peptides between an aqueous conformation where the backbone amide protons
are solvent exposed and a lipophilic conformation where these participate in
intramolecular hydrogen bonds. Temperature Coefficient NMR (TC-NMR) can be used to
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determine if the amide protons are participating in intramolecular hydrogen bonds
(IMHBs) under lipophilic conditions by determining how far the peaks shift in response to
temperature change. First a suite of 2D-NMR experiments were ran on Peptide 44 to fully
assign the amide proton chemical shifts (Table 4.3; Figure 4.2) then the TC-NMR
technique was used to determine whether or not amide protons were participating in
IMHBs under the lipophilic conditions of 30% TFE-d3 (a solvent known to induce peptide
secondary structures) in D2O (Table 4.4; Figure 4.3). Using this temperature sensitivity
analysis, if amide protons move less than -2.5 ppb/K then they are potentially
participating in IMHBs, but if they move more than -4.5 ppb/K then they are not likely to
be involved in IMHBs.62 Based on the suite of 2D-NMR experiments (DQF-COSY; TOCSY;
ROESY) the 5 backbone and the cyclization linker amide protons were assigned in addition
to others of importance . Upon running the TC-NMR experiment from 295-320°K, the
temperature coefficient for all amide protons were greater than the -4.5 ppb/K cut-off
described by literature, indicating that none of these participate in IMHBs under lipophilic
conditions.
4.2.3 Optimization of BRAF 508-513 Cyclized DIF Peptide for Passive Cell Permeability
using REPLACE
After significantly truncating the cyclic peptide to the BRAF 508-513 cyclic
sequence while retaining reasonable activity (44; Table 3.1), a compound suitable for
further application of REPLACE was obtained. Using the REPLACE method to identify
fragment replacements for the exocyclic sequences was attempted to recover lost affinity
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while also increasing the lipophilicity of the overall compound. N-terminal and C-terminal
capping groups were initially tested in the linear FLIP context of the BRAF 505-518
sequence, using the ITF assay carried out by the Kontopidis lab, in order to efficiently
determine contribution of the FLIP without complicated cyclization and purification
methods, respectively replacing the exocyclic sequence of the native sequence with the
desired PLA capping group (Table 4.5).
The first N-terminal capping group to be used was benzoic acid (N1; Table 4.6)
coupled to the N-terminal amine replacing the “LRK” sequence. Others included those
incorporating extra methylenes to optimize the position of the phenyl ring to the W450
side-chain. The incorporation of N1 in the FLIP 45 (Kd = 0.050 µM; Table 4.5) resulted in
an enhancement of binding compared to 1. The N2 FLIP (46; Kd = 0.084 µM) slightly
hindered binding but was still better than peptide 1. FLIPS containing the N3 and N4 PLAs
(2 and 3 methylenes respectively; FLIPs 47 and 48) were determined to be insoluble under
testing conditions.
Potential C-terminal capping groups were also tested in the linear FLIP context,
replacing the LLFMG sequence of BRAF (residues 505-518) with fragment analogs of 2-(4(isopentyloxy)phenyl)ethan-1-amine (Table 4.6). The incorporation of C2 (49), C3 (50),
and C4 (51) PLA capping groups resulted in linear FLIPs exhibiting a Kd of 0.020, 0.380,
and 0.570 µM respectively (Table 4.5). The incorporation of all the N-/C-terminal capping
groups in the linear FLIP context resulted in sub-micromolar direct binding affinities
similar to results obtained for the cyclic peptides.
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FLIP 52 combining the N2 and C4 capping groups in the linear context was synthesized
and tested. This compound had a Kd = 0.280 µM (Table 4.5), in which the high potency
of the N2 group rescued the weak binding interaction of the C4 capping group. . FLIP 54
included the two highest affinity capping groups identified in the linear context along with
NMe-Arg and the reverse-β-turn stabilizing sequence “aPA” and yielded a Kd of 0.017 µM.
This data resulted in the new lead peptide sequence for direct binding and was designed
to have both reduced size and increased lipophilicity required for passive cell permeability
(Table 4.2).
4.2.4 Study of Passive Cell Permeability
The passive permeability of peptides was tested using a PAMPA (Parallel Artificial
Membrane Permeability Assay) assay kit where compounds are incubated in a two well
system divided by an artificial membrane and cell permeability is assessed via UV
detection of the receiver well after incubation. Peptides 17, 36, 44, and 55, along with
the low, medium, and high permeability controls, were tested in this assay for passive
diffusion and results were accessed by UV absorption using a plate reader. As described
in the kit, the controls performed as expected but the results obtained from the peptide
samples were more ambiguous due to interference of the DMSO absorbing at the lower
wavelengths. The experiment was repeated for peptides 44, 54 and 55, using LCMS to
determine the compound concentration in the acceptor cell solution, and there was no
detectable signal for any of those tested. Furthermore, peptides 54 and 55 which
modified in the hope of making them cell permeable by incorporation of lipophilic capping
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groups and through N-methylation and substitution of proline, or through complete
replacement of some contiguous but less important residues with an alkyl chain, were
tested in the PAMPA assay. Using an LCMS analysis these none of these compounds were
detected in the acceptor cell.
4.3 Discussion
The objective of this chapter was to optimize the physiochemical properties of the
lead peptides so that they better adhere to the beyond rule of 5 (bRo5) guidelines for
passive cell permeability of macrocyclic peptides.50 In a study conducted by Nielsen et al.
a large library of orally bioavailable cyclic peptides was examined for bRo5 characteristics.
This study observed that peptides with molecular weight (MW) up to 1300 daltons, a LogP
range from 1-8, a maximum of 6 hydrogen bond donors (HBDs) and 20 hydrogen bond
acceptors (HBAs), and a topological polar surface area (tPSA) of <300Å2 had the greatest
oral availability (Table 4.1), meaning that when the drug was administered orally, then a
certain percentage of the administered dose makes it to the therapeutic target.50 The
statistic of oral bioavailability is dependent on several parameters including absorption,
metabolism, stability, and cell permeability. Though cell permeability is only one factor
of oral bioavailability based on these properties and ability to hydrogen bond, or lack
there of, the original BRAF DIF peptide 1 was modified as follows.
After identifying an effective peptidic inhibitor (1) of BRAF dimerization, the three
main characteristics where which needed to be addressed in order to generate a more
drug-like compounds, were reduction of MW, increasing its lipophilicity, and
74

conformational flexibility of 1 (Table 4.2). Starting with cyclization to reduce the number
of rotatable bonds, several macrocyclic peptides were designed and tested resulting in 36
which was connected by a nine atom lactam bridge between residues 508 and 513. This
peptide possessed a Kd = 0.06 µM and became the lead compound for the development.
Further modifications to make the peptide more drug-like included reducing the size of
the macrocycle by a series of exocyclic truncations. Based on these experiments, 44 was
identified as the core macrocycle sequence containing only the cyclic residues of 508-513
from the precursor peptide 36. Peptide 44 had a Kd = 0.30 µM, which although resulted
in a 5-fold decrease in affinity relative to 36, reduced the molecular weight to within the
bRo5 guidelines and provided the basis for further optimization and application of the
REPLACE strategy.
Based on bRO5 guidelines, further optimization was attempted by increasing
lipophilicity of the peptide and decreasing the number of HBDs and HBAs all of which will
address issues with a high tPSA. As mentioned, there are several studies which attribute
cyclic peptide’s cell permeability to “the chameleon effect”.53 This phenomenon occurs
due to a peptide’s ability to solvent expose polar groups under aqueous conditions and
to be flexible enough to change conformation and sequester these to allow entry to the
cell membrane, thus desolvating in an energy efficient manner. Furthermore, the peptide
must be able to favorably resolvate upon exiting the cell membrane into the cytosol for
example as occurs with cyclosporine A. As such, cell permeability is attributed to the
ability of peptides to form intramolecular hydrogen bonds (IMHBs) transversely across
the macrocycle. This sequesters polar groups (HBD/HBAs) from the lipophilic
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environment and is complemented by N-methylated of amide NH’s that do not form
IMHBs thus making the compound more lipophilic.
To assess whether the core macrocycle 44 can form IMHBs, the peptide was
analyzed via TC-NMR (Temperature Coefficient NMR; Figure 4.3; Table 4.4) after a suite
of 2D-NMR techniques (Figure 4.2; Table 4.3) was used for chemical shift assignment.
This technique is used to analyze the temperature dependence of backbone amide
protons in a solvent such as trifluoroethanol-d3 (TFE-d3), which is thoughts to mimic the
hydrophobic environment of a membrane and also to induce peptide secondary
structure. If the NH proton in question is participating in an IMHB then the proton will
exhibit less of a temperature-dependent change in the chemical shift (0 to -2.5 ppb/K)
since its solvent exchange is decreased by hydrogen bonding. Conversely, protons not
participating in IMHBs will shift more dramatically (greater than -4.5 ppb/K) with an
increase in temperature. When 44 was tested in this experiment, all amide protons
exhibited temperature-dependent shift characteristics suggesting that none of them
participate in IMHBs (Table 4.4). This result indicates that the backbone amide nitrogens
could be N-methylated as long as they don’t play a role in BRAF binding. Incorporation of
an N-methylated arginine at position 509 (41) did not significantly compromise binding
and a proline at position 511 (43) resulted in enhancement of binding potency (due to
stabilization of the reverse-β-turn), each while reducing the number of hydrogen bond
donors (Table 4.5).
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N and C-terminal truncation (“LRK” on the N-terminus and “LLFMG” on the Cterminus) of 36 to generate 44 resulted in loss of important binding interactions with
BRAF-W450 and the deep hydrophobic pocket to which peptidic L515 bound. The
REPLACE strategy (Replacement with Partial Ligand Alternatives through Computational
Enrichment) was used in order to discover more drug-like alternatives for the truncated
exocyclic sequences. In order to develop N-/C-terminal capping groups, small molecule
libraries were searched for appropriate compounds which would provide pi-stacking
interactions on the N-terminus with W450 as well as a lipophilic interaction with the
hydrophobic pocket to which L515 originally bound.

Capping groups were then

computationally modeled in their appropriate location to assess the feasibility of
incorporating them into the peptide sequence. The capping groups were then initially
tested experimentally in the context of the truncated linear peptide for ease of synthesis
and purification (Table 4.5). The peptides were then tested in the ITF assay to assess
direct binding affinity for the BRAF DIF. N-terminal capping groups were varied by
increasing the number of methylene groups in the benzoic acid portion (Table 4.6), of
which the two longest were insoluble with the optimal of these being benzoic acid itself
(45) and its face-to-edge pi-stacking conformation with the protein W450 resulted in
Kd=0.05 µM. The C-terminal groups were analogs of 2-(4-(isopentyloxy)phenyl)ethan-1amine (Table 4.6). The tightest binding C-cap was C2 with a para substituted phenol ether
(49) and a Kd=0.02 µM (Table 4.5). Interestingly, all linear, capped peptides had direct
binding affinities on par with the best cyclic peptides. Furthermore, when the poorly
binding C4 group and tightly binding N2 group were combined in the linear context, the
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resulting peptide 52 had a relatively equivalent binding potency to the cyclic, uncapped
version (44). This shows that the N2 cap rescued the inefficiently binding C4 cap thus
confirming the utility of these non-peptidic capping groups.
After further optimization, the development of 36 produced the lead peptide, 54
for this study in terms of binding affinity and modifications predicted to both increase
affinity and cell permeability. Furthermore, a peptidomimetic 55 which replaced the
“aPA” sequence of 54 with an octyl linker was synthesized to realize cell permeability by
increasing the overall lipophilicity and decreasing the number of HBD/HBAs. Several
peptides and FLIPS including 1, 36, 44, 54, and 55 were tested for passive cell permeability
in the PAMPA assay. After incubation of the peptides as described, the acceptor cell was
analyzed via LCMS to determine the rate of passage through the membrane. Based on
the results of the PAMPA assay, there was no evidence of passive permeability of any of
the peptides or FLIPS. This may be due to the compounds not being able to efficiently
transition between hydrophilic and hydrophobic conformations which allow for masking
of the remaining polar surface area. Additional work should be completed to mask
HBD/HBAs while still maintaining aqueous solubility.
4.4 Conclusion
In efforts to convert DIF peptide 1 (GVLRKTRHVNILLFMGYST) into a drug-like and
ultimately an orally available compound, the native sequence has been modified through
cyclization and truncation to reduce the overall size and number of rotatable bonds of the
initial sequence, resulting in 44 (KRHVAE) which contains less than half of the original size
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and significantly fewer rotatable bonds compared to Peptide 1. Further investigation into
the ability of the cyclic peptide to change conformation when passing through a lipophilic
environment was evaluated using TC-NMR methods. The data suggests that none of the
backbone amide protons participate in intramolecular hydrogen bonds with the transcyclic carbonyls under lipophilic conditions.

This affects the peptide’s ability to

dynamically pass through the cell membrane by way of energetically favorable
conformational changes that mask hydrogen bond donors. Results suggest that Nmethylation of the backbone amide groups can be undertaken to increase lipophilicity.
Furthermore, the REPLACE method was utilized in the generation of FLIPS capped with
small molecule fragments which enable more efficient binding and increased lipophilicity.
All FLIPs had sub-micromolar binding affinity in the linear context, suggesting successful
and effective replacement of the exocyclic sequences. Furthermore, incorporation of
both groups (N2 and C4) in the same compound was shown to recapitulate the lost
binding affinity from truncation of the exocyclic sequences in the linear context (52). The
PAMPA assay was used to assess passive permeability of the lead peptides and FLIPS
however no detectable passage through the artificial membrane was observed. Though
unsuccessful by this measure, significant progress has been made in the optimization of
DIF peptide physiochemical properties, ability to tightly bind BRAF, and obtaining proof
of concept for inhibiting BRAF mediated paradoxical activation. Future endeavors will
involve further N-methylation studies of the 508-513 macrocycle, further REPLACEment
of the cyclic sequence of FLIP 54, and incorporation of cell penetrating peptide moieties
through tri-functional cyclization linkers.
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4.5 Experimental
4.5.1 Temperature Coefficient NMR Spectroscopy
The peptide sample was dissolved in minimal DMSO-d6 and was then diluted with
a solution of 30% trifluoroethanol-d3 (TFE-d3) and D2O. The 1D spectra were obtained
using a Bruker 400 MHz NMR equipped with a cryoprobe using a pre-saturation pulse
sequence designed to suppress the signal of the water peak. The experiments were ran
using the TFE-d3 as the lock solvent and were ran for 16-32 scans each at 295, 300, 305,
315, and 320ᵒ K. Following runs, spectra were checked for the presence of the correct
number of amide proton doublets between 7.0-9.0 ppm. To determine the temperature
coefficient of each amide proton, Equation 3 was used, where “S” is the chemshift (ppb)
of each respective amide peak at either 295ᵒ K or 320ᵒ K and “ΔT” is the change in
temperature between the two extremes. The need for full characterization through a
suite of 2D NMR spectra was dependent on clarity of the 1D spectrum at any given
temperature.
(𝑆320𝐾 − 𝑆295𝐾 )
𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟑: 𝑇𝐶 = [
]
∆𝑇
4.5.2 Characterization of Peptides by 2D NMR Spectroscopy
For the characterization of peptides, the same sample and instrument were used
as for the TC-NMR experiments. First a 1D H1 NMR was obtained using the pre-saturation
pulse sequence, then a double quantum filter corelated spectroscopy (DQF-COSY)
experiment was ran to identify the amide protons and their adjacent αCH protons. In this
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experiment, there was no correlation for the N-terminal residue due to rapid exchange of
the deuterium isotope on the amine. Once the amide and αCH protons were identified,
a total correlation spectroscopy (TOCSY) experiment was ran. This experiment was used
to identify each residue based off of their spin system pattern which is representative of
the consecutive adjacent protons in the residue side-chain. Lastly, a rotating frame
overhauser effect spectroscopy (ROESY) experiment was ran which correlates αCH
protons which are close in space to the adjacent residue’s amide proton. In this
experiment, the sequence of the peptide can be identified, resolving the identity of any
duplicate residues which may be present in the sequence.
4.5.3 PAMPA Assay
The PAMPA assay was accomplished using a PAMPA assay kit purchased from
BioAssay Systems, which included the donor plate, acceptor plate, UV plate, lecithin,
dodecane, and high, medium, and low permeability controls. Each tested compound was
dissolved in DMSO to make a 10 mM stock solution (standards were already 10 mM in
DMSO) which was diluted with phosphate-buffered saline (PBS) to give a 500 µM solution
of the test compounds and standards. The lecithin was dissolved in dodecane as
instructed by the kit protocol to make a 4% lecithin in dodecane solution, this solution
was then used to wet the membrane at the bottom of the donor wells. The acceptor
plate was then loaded with 300 µL of PBS and the acceptor wells were loaded with the
500 µM test compound solutions (200 µL). The donor plate was then stacked onto the
acceptor plate so that the acceptor PBS solution made complete contact with the bottom
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side of the membrane. The plates were then covered and allowed to incubate at 38ᵒ C
for 18-24 hours. The following day, the donor and acceptor solutions were collected from
the plate to stop the experiment.
The kit suggests quantification of acceptor well concentration using the included
UV plate, but the low absorbance wavelength of the peptides in conjunction with the
interference of the DMSO made it impossible. The concentration of the acceptor well
was quantified by LCMS methods. Solutions of test compounds and standards were made
at 500, 250, and 125 µM and 20µL aliquots were injected onto the LCMS. The combined
absorbance of the sample peak at 215 and 254 nm were plotted verses concentration to
establish each sample concentration curve. The acceptor and donor well solutions were
then injected onto the LCMS and the concentration was determined based on the
detected absorbance peak.
4.5.4 Synthesis of Double Capped Cyclic Peptides (FLIPS)
Compounds which were designed to be capped on both the N-/C-terminus were
synthesized on a chlorotrityl chloride (CTC) polystyrene resin which allows for cleavage of
the peptide under very mild conditions without deprotection of sidechains. The peptide
was loaded onto the resin by 2x 5 hour treatments with the AA (2 eq) and DIPEA (4 eq)
dissolved in a 1:1 solution of DMF and DCM. After loading, the unfunctionalized groups
on the resin were capped by treatment with a solution of DCM/MeOH/DIPEA (80:15:5)
for 30 min. The resin was then washed 3x each with DMF, DCM, and DMF again. The rest
of the linear synthesis was completed as previously stated in section 3.4.1 except that the
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coupling reactions were completed in a 1:1 DMF/DCM solution to promote swelling of
the resin.
The N-terminal capping group was attached by treating the free amine N-terminus
2x 2 hours with a solution containing DIPEA (4 eq) and the respective acid chloride capping
group (2 eq). The resin was then washed 3x each with DMF and DCM. The cyclization
residues were then Alloc/Allyl deprotected by 4x 10 min treatments with a solution of
tetrakis(triphenylphosphine)palladium catalyst (cat.) and phenylsilane (100 µL) in DCM.
The resin was then washed 10 times with DCM to remove all of the catalyst. The peptide
was then cyclized by treatment with HATU (2 eq) and DIPEA (4 eq) in 1:1 DMF/DCM
overnight. In the morning the sample was washed 3x each with DMF and DCM.
The peptide was then mildly cleaved from the resin by treatment with a 1% TFA in
DCM solution 2x for 5 min each. The solution was then collected and immediately
rotovapped to minimize sidechain deprotection. The C-terminus was capped with its
corresponding amine by treatment with the amine capping group (1 eq), HATU (1 eq), and
DIPEA (4 eq) for 8-12 hours. The reaction was then rotovapped to dryness, dissolved in
DMSO, and was flash purified on the Biotage Sfar C18 12g column using mass-directed
collection methods. Following purification, fractions were combined, rotovapped, and
were then treated with the deprotection solution TFA/TIPS/H 2O (94:5:1) for 1-12 hours
to remove sidechain protecting groups (duration depends on which protecting groups are
to be removed). The solution was rotovapped off and the final peptide was purified by
semi-preparative LCMS as described in Section 3.4.4.
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TABLE 4.1: PASSIVE CELL PERMEABILITY GUIDELINES

Guidelines were developed by authors above with Lipinski46 and
Veber47 referring specifically to passive permeability of small
molecules and Nielsen50 is describing passive permeability of
cyclic peptides.
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TABLE 4.2: PHYSIOCHEMICAL PROPERTIES OF PEPTIDES FOR CELL PERMEABILITY
ID
1
36
42
43
44
52
53
54
55

MW
HBD HBA cLogP tPSA
(g/mol)
GVLRKTRHVNILLFMGYST Linear 2205.66 28
26
N/A
885
LRKKRHVAELLFMG
Cyclic 1679.12 20
18 -2.34 651
KRHVAELLFMG
Cyclic 1281.59 15
14 -1.06 476
KRHPAELLFMG
Cyclic 1278.7
14
14 -1.50 467
KRHVAE
Cyclic 719.85
10
9
-3.94 330
N2-TRHVNI-C4
Linear 1032.26 11
12
0.98 363
N1-KRHVAE-C2
Cyclic 1014.24 10
11
1.94 328
N1-K-MeR-a-PAE-C2
Cyclic 960.19
7
10
3.13 286
N1-K-MeR-Octyl-E-C2
Cyclic 862.13
6
7
3.71 237
Sequence

Type

Description of physiochemical properties of key peptides and FLIPs as assessed by
Lipinski’s rule of 5 as well as the more relevant beyond the rule of 5 criteria.
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TABLE 4.3: ITF DIRECT BINDING ASSAY DATA OF BRAF DIF FLIPS
ID
45
46
47
48
49
50
51
52
53
54

BRAF
Residues
508-518
508-518
508-518
508-518
505-513
505-513
505-513
508-513
508-513
508-513

Sequence

Kd (µM)

N1-TRHVNILLFMG
N2-TRHVNILLFMG
N3-TRHVNILLFMG
N4-TRHVNILLFMG
LRKTRHVNI-C2
LRKTRHVNI-C3
LRKTRHVNI-C4
N2-TRHVNI-C4
N1-KRHVAE-C2
N1-K-MeR-a-PAE-C2

0.050 ±0.006
0.084 ±0.024
------0.020 ±0.010
0.380 ±0.096
0.570 ±0.092
0.280 ±0.088
---0.017 ±0.006

Direct binding coefficients of FLIPs which are going through iterative
REPLACEment of exo-cyclic sequences to make the peptides more druglike.
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TABLE 4.4: TEMPERATURE COEFFICIENTS OF
BACKBONE AMIDE PROTONS OF PEPTIDE 44
Residue ppm @ 295ᵒ
Lys*
Arg
His
Val
Ala
Glu

7.595
8.675
8.502
7.903
7.919
7.994

ppm @ 320ᵒ
K
7.466
8.532
8.368
7.758
7.797
7.856

TC (ppb/K)
-5.16
-5.72
-5.36
-5.80
-4.88
-5.52

TC values greater than -4.5 ppb/K indicate nonparticipation in intramolecular hydrogen bonds (IMHBs)
and TC values of 0 to -2.5 ppb/K indicate participation of
amide protons in IMHBs. The symbol (*) indicates that
the value is representative of the side-chain amide in the
cyclization linker.
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TABLE 4.5: PROTON ASSIGNMENTS OF PEPTIDE 44

Residue
Lys
Arg
His
Val
Ala
Glu

αNH
N/A
8.532
8.368
7.758
7.797
7.856

αCH
N/A
4.333
4.562
4.034
4.232
4.237

Proton Assignments (ppm)
βH
γH
δH
εH
ζH
1.829
1.326
1.473 3.170 7.466
1.783
1.666
3.139 7.051
3.317; 3.170
1.829
1.473; 1.326
1.336
1.880
2.296; 2.123

The chemsifts were determined from the suite of 2D NMR experiments ran at
320ᵒ K in 30% TFE and water using the pre-sat pulse sequence on Bruker 400 MHz
NMR equipped with a cryoprobe.
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TABLE 4.6: N-TERMINAL AND C-TERMINAL CAPPING GROUPS

N-terminal capping groups were designed for pi-stacking interactions with
BRAF-W450 and C-terminal groups were designed to bind a deep hydrophobic
pocket adjacent to the R509 binding pocket.

89

FIGURE 4.1: REPLACE STRATEGY SCHEME: Systematic conversion of segmented
peptides into more drug-like compounds by iterative conversion using
computationally designed partial ligand alternatives (PLAs) to make fragment
ligated inhibitory peptides (FLIPs).
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FIGURE 4.2: TC-NMR SPECTRA OF PEPTIDE 44: NMR spectra were taken from 295-320ᵒ
K showing that all amide protons shifted at temperature-dependent rate faster than that
associated with IMHBs.
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FIGURE 4.3: 2D NMR SPECTRA OF PEPTIDE 44: The above overlapping spectra consist of
a DQF-COSY (blue and yellow), TOCSY (red), and ROESY (green and purple). A.) Shows the
spin systems in the TOCSY for each 1D amide peak for residue identification. B.) Shows
the step-wise correlation of adjacent residues using the DQF-COSY amide peaks and the
ROESY spatial correlation peaks. There is not a DQF-COSY peak for the N-terminal amine
on the Lys due to rapid deuterium exchange.
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CHAPTER 5
OFF-TARGET EFFECTS, CONCLUSIONS, AND FUTURE DIRECTIONS
5.1 Introduction
A major concern in drug discovery is to ensure specificity of clinically relevant
compounds for their intended target for the induction of the intended pharmacological
response. Small molecules making up most approved drugs generally bind to deep
pockets from catalytic sites occupied by substrates or co-factors required for enzymatic
activity. For example, Type I kinase inhibitors bind to the ATP binding site to inhibit
catalytic phosphorylation of the kinase substrate by blocking ATP. A drawback however is
that ATP binding sites are similar in the sense that they natively bind the same compound.
As a result, Type I kinase inhibitors have the potential to bind multiple kinases, causing
off-target interactions and side effects, thus these types of drugs require extensive
optimization to minimize these risks.
Off-target binding can be evaluated through in silico modeling through docking of
lead compounds into the intended binding sites of similar proteins and calculating binding
interactions. Experimentally there are a number of methods, including biochemical
screening of compounds against kinase panels using recombinant purified proteins, to
determine off-target binding. Cellular assays can be used to determine off target binding
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as well using biotinylated ligands; for this experiment, cells would be incubated with
tagged compounds, lysed, purified with streptavidin functionalized media, and off-target
binders would be identified by western blot analysis.
The target of the developing cyclic peptidomimetics from this research is the BRAF
dimer interface, which consists of the highly conserved (among RAF family members and
KSR), short reverse-β-turn sequence of BRAF residues 502-521. Dimerization of BRAF is
mediated by the key interaction of the arginine handshake motif where R509 of each
monomer forms an anti-parallel confirmation and a cation-induced dipole interaction
with the partial negative charge of the C-terminal end of the αC helix of the adjacent
monomer. Though this mechanism of activation is highly conserved between RAF
isoforms, as well as KSR proteins, this is not necessarily a common motif of activation of
all +500 kinases in the kinome.
Investigation of the BRAF DIF binding motif through sequence similarity searching
has led to the identification of several proteins which may be potential off-target binders
of the lead DIF inhibitors and these include RIPK3 (Receptor-interacting protein kinase 3),
DAPK3 (Death-associated protein kinase 3), and SH2D3C (Sh2 domain-containing protein
3C). Of the three proteins, DAPK3 and SH2D3C contain about 60% sequence identity of
the BRAF DIF 500-520 sequence. Upon further investigation of the crystal structures of
these similar proteins, neither homologous sequence appears to be directly involved in
protein dimerization. Furthermore, the similar region of SH2D3C (PDB 3T6G) appears to
be part of two α-helices whereas the sequence associated with DAPK3 (PDB 1YRP)
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appears to have a similar secondary structure to that of BRAF with the sequence being
found largely in a random coil and bridging between an α-helix and a β-sheet. Though
this parallel is interesting, the lack of involvement of this sequence in a dimerization
interface with DAPK3 led to the conclusion that the RIPK3 protein was the most relevant
since the sequence was encompassed in a dimer interface.
Receptor-interacting protein kinase 3 (RIPK3) is part of a larger family of kinases
which regulate the necroptotic cell death pathway. Necroptosis is an inflammatory cell
death pathway whereas apoptosis is a non-inflammatory one.

In the necroptosis

pathway, studies suggest that activated RIPK1 (receptor-interacting protein kinase 1)
interacts with RIPK3 through the RHIM (RIP homo-typic interaction motif) to induce
autophosphorylation of RIPK3.63,64 The activated RIPK3 then recruits and phosphorylates
MLKL (mixed lineage kinase domain-like protein), which oligomerizes at the plasma
membrane, leading to membrane leakage and cell death. Studies done by Raju et al. show
similarities in RIPK3 and BRAF dimerization motifs in which dimerization is centered
around an arginine-handshake motif.63 This is not only interesting due to the similarity of
the two dimerization motifs, but also since the proteins themselves play opposing roles
in cell survival, where BRAF is the gatekeeper kinase for cell proliferation and
differentiation, and RIPK3 initiates the necroptosis pathway and is responsible for
regulation of programed cell death. In the scope of the developing BRAF DIF inhibitors,
they have the ability to bind the BRAF DIF and inhibit proliferation through the MAPK
pathway, but the potential off-target inhibition of RIPK3 may cause opposing effects by
inhibition of the necroptosis cell death pathway simultaneously.
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5.2 Results
5.2.1 hRIPK3 Homology Model
To qualitatively study the crystal structure of human RIPK3 protein structure, a
homology model of the protein was created since there is no previously published crystal
structure for hRIPK3. The model was created by alignment of the human RIPK3 sequence
to the murine RIPK3 sequence, which already has a crystal structure (PDB 4M66) and is
assumed to have a similar secondary and tertiary structure. The protein structure of
hRIPK3 was then modeled using the mRIPK3 crystal structure as a template to create the
homology model.
5.2.2 Comparison of BRAF/hRIPK3 Dimer Interfaces and DIF Peptides
Comparing the two proteins, each appears to form a dimer in a similar manner
with a consecutive sequence forming a reverse-turn between an α-helix and β-sheet at
the interface of the two monomers. For BRAF, the dimer interface is composed of
residues V504-G518 (VLRKTRHVNILLFMG; Figure 5.3A) whereas for hRIPK3, it is made up
of residues V48-G64 (VKAMASLDNEFVLRLEG; Figure 5.3B).

Though the sequence

alignment for the dimer interface of the two proteins has a low similarity, it cannot be
ignored that the two proteins appear to dimerize in a similar fashion with a continuous
reverse-turn encompassing the majority of the dimer interface as well as utilization of an
Arg residue in the DIF (Figure 5.3C). As a method of confirming similar binding of DIF
peptides to the two proteins, a linear peptide of the hRIPK3 DIF (56; MASLDNEFVLRLEG)
was synthesized and was tested for BRAF direct binding potency in the previously
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mentioned intrinsic tryptophan fluorescence assay (Chapter 2).

Interestingly, 56

exhibited Kd = 1.11 µM which was a 3-fold increase in potency compared to 1 (Kd = 3.84
µM). Granted, it was shown in the linear peptide optimization that minimal changes to
the sequence can tremendously influence the binding potency in the linear context, but
it cannot be ignored that the linear hRIPK3 DIF peptide did have a legitimate binding
interaction to the BRAF protein.
5.2.3 Computational Investigation of Homodimers of BRAF/hRIPK3/mRIPK3
Utilizing the BRAF (PDB 4E26), mRIPK3 (PDB 4M66), and hRIPK3 (Homology
Model) homodimer crystal structures, the binding determinants of homodimers were
evaluated using Discovery Studio 3.0. The overall interaction energy for the homodimers
were -222.2, -208.6, and -160.8 kcal/mol for BRAF, mRIPK3, and hRIPK3, respectively. This
data suggests that BRAF and mRIPK3 form more energetically stable homodimers than
hRIPK3, but this doesn’t necessarily suggest similarity in DIF binding. To compare the DIF
sequences specifically, the interaction energy calculation report was focused at the
contributions of DIF residues for homodimer formation. Based on the results from this
study (Figure 5.1), mRIPK3 was shown to rely heavily on DIF residues R69 and E71 (-26.2
and -32.0 kcal/mol respectively) for homodimer formation, of which R69 of mRIPK3 is
similar in function and location as R509 in BRAF. As for hRIPK3, homodimer formation
appears to rely heavily on E58 (-45.7 kcal/mol) in a similar manner to mRIPK3 binding to
a Lys residue outside of the DIF residues in question, and to a lesser extent R62 (-16.3)
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which varies dramatically in DIF location from both BRAF and mRIPK3 and appears to bind
D56 rather than the induced dipole of the αC-Helix.
5.2.4 Computational Investigation of BRAF/hRIPK3 Heterodimer Interactions
In a similar manner as with the homodimer study, the interactions in a possible
BRAF (PDB 4E26) and hRIPK3 (Homology Model) heterodimer were studied by creating a
model in which the two monomers were combined, minimized, and the interaction
energy of each monomer for the other was calculated (Figure 5.2). According to the
computational modeling, dimer contributions of the BRAF DIF for hRIPK3 (-92.6 kcal/mol)
were strictly dependent on R509 (BRAF) with interaction energy of -55.9 kcal/mol (Figure
5.2; Figure 5.4). In the inverse manner, the heterodimer contributions of hRIPK3 DIF for
BRAF (-115.6 kcal/mol) were largely reflective of D56 (hRIPK3; -34.2 kcal/mol) and to a
lesser extent through A53, L55, E58, and E64 (hRIPK3), with interaction energy
calculations of -16.1, -14.3, -19.0, and -18.4 kcal/mol, respectively. Interestingly, the R509
(BRAF) counterpart R62 (hRIPK3) seems to indicate the disfavorable interaction energy of
+16.2 kcal/mol.
5.3 Discussion
Based on the BRAF DIF sequence similarity search, DAPK3, SH2D3C, and RIPK3
have sequence identity, but from a qualitative analysis of the similar portions of these
crystal structures, DAPK3 and SH2D3C were deemed to have dissimilar secondary and
tertiary structure and thus were not considered to be relevant. RIPK3 however from
comparison of its crystal structure to BRAF, dimerizes similarly and thus was further
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investigated. Due to the human RIPK3 protein not having an available crystal structure, a
homology model based on the murine RIPK3 template structure was developed.
According to the generated homology model, the hRIPK3 dimer interface has similar
secondary structure with a reverse-turn connecting an α-Helix and β-sheet. Upon
analyzing the binding interface, it can be observed that the arginine in the hRIPK3 dimer
interface is on the opposite side of the reverse-turn in comparison to BRAF and was more
likely to bind to an aspartate residue rather than the induced dipole of the α-Helix.
Furthermore, homodimer interaction energy calculations of the hRIPK3 homology model
suggested that the major contributor to dimer stability was E58 which had a strong
electrostatic interaction with a lysine which was not contained in the dimer interface.
Additionally, in the BRAF/hRIPK3 heterodimer studies, it appears that in this context,
dimer stability is largely reliant on the interaction of R509 (BRAF) with D56 and the Cterminus of the α-helix adjacent to the hRIPK3 DIF (Figure 5.2; Figure 5.4). When studying
this in the inverse context, it was observed that there are several other hRIPK3 DIF
residues which contribute to dimer formation, but to a lesser degree.
Though the homodimer computational studies were informative for dimer
interface contributions for hRIPK3, this is only a model and more definitive answers
require an experimental crystal structure. Interestingly, the hRIPK3 peptide 56, when
tested for direct binding to BRAF in the ITF assay, 56 had tighter binding than the original
peptide 1 which was the linear sequence of the BRAF DIF. Further studies to investigate
the reverse, i.e. binding of BRAF DIF peptides to hRIPK3 needs to be done to more
completely identify off-target interactions.
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5.4 Conclusion
Overall, this study was productive in the sense that the homology model of hRIPK3
was generated and the alignment described by Raju et al was replicated.63 Furthermore,
it was found that the hRIPK3 DIF peptide 56 showed binding interactions with BRAF and
indicating that there are potential off-target proteins other than RAF family members and
KSR proteins which may be influenced by the BRAF DIF peptides. Further experiments
still need to be done, such as a kinase panel testing for off-target effects of the lead
compounds described previously in the cyclic BRAF DIF peptide library. Other possible
experiments could include the use of biotin conjugated DIF peptides for identification of
off-target interactions in the cellular context.
5.5 Future Directions
Other than the previously mentioned experiments for off-target interactions of
DIF peptides, there are several other areas which need to be addressed for advancement
of this project. Firstly, although the peptides have been optimized for binding to the
truncated BRAF protein and biochemically tested using the ITF and ITC assay, peptidic and
FLIP versions of the cyclic peptide need to be tested in cells to confirm that there is still
pharmacological responses under paradoxical activation conditions. Also since it has not
been shown that peptides or FLIPs are able to passively enter the cells through diffusion
through the PAMPA assay, cellular experiments using electroporation as described in
Section 2.2.1 could be repeated with cyclic, lead peptides and FLIPS. Another possibility
would be incorporation of the cell penetrating peptide sequence such as TAT to induce
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cell penetration without potentially damaging the cell in electroporation. In the peptide
context, TAT could be attached through the N-Terminus, additionally, in the FLIP context
TAT can be attached through a tri-functionalized cyclization linkage. In the past, the
McInnes lab has had some success utilizing cyclization methods through the Ugi 4component reaction (57; Kd = 0.55 ± 0.04 µM; Figure 5.4) and through use of a 1,3dibromobenzene linkage (58; Kd not tested; Figure 5.4) which could be utilized for
incorporation of the TAT sequence in the cyclization linker which does not come into
contact with the BRAF DIF binding surface according to molecular modeling data.
The largest area of focus for the progression of this project is the enhancement of
cell permeability of the lead peptide and ability of lead compounds to reach the target
protein, as well as oral bioavailability. In this sense, the largest contributing factor to this
in the peptide or FLIP context would be N-methylation of the backbone amides without
interfering with the binding affinity of the compound itself. Another method aside from
merely N-methylating the backbone would be the development of peptoids. These are
peptide like compounds based on N-susbituted glycine which are functionalized through
the amide nitrogen rather than the αC of the amino acid. This intrinsically reduces the
number of HBDs by removing amide hydrogens. Furthermore, optimization of the
macrocycle could be accomplished through further application of the REPLACE strategy
to replace it with fragment like molecules which promote increased potency, enhanced
cell permeability, and proteolytic stability of the overall compound.
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5.6 Experimental
5.6.1 Qualitative Assessment of BLAST Search Hits
Upon BLAST searching for the BRAF DIF sequence to discover potential off-target
interactions, hits with greater than 50% identity were examined. Crystal structures were
downloaded from the protein data bank and matched sequences were identified. The
secondary structure of the hit sequence was then qualitatively scored based on whether
the sequence had a reverse-β-turn structure like that of BRAF (PDB 4E26).
5.6.2 Homology Model Development of Human RIPK3
The homology model of hRIPK3 was created in Discovery Studios 3.0. The
sequence of hRIPK3 was downloaded from a UniProt search and was aligned with the
mRIPK3 sequence (PDB 4M66) in the Discovery Studios program. The dimer sequences
were then separated into separate files and monomers of hRIPK3 sequence were
separately aligned over the 3D structure of the mRIPK3 crystal structure. Upon alignment,
the monomers were then combined back into a single file to create the homology model
and were then compared to the BRAF dimer in one window.
5.6.3 Homodimer Interaction Energy Calculations
Each homodimer, whether from a crystal structure or homology model was
minimized in the Discovery Studios 3.0 software using the CharmM forcefield, for general
protein modeling work, with a max number of steps of 2000 and GBSW solvent algorithm.
Once minimized, the interaction energy was calculated as follows: atoms on protomer A
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which are 12 Å from protomer B were selected as the binding site, protomer B was
selected as the ligand, and the ID-DD dielectric model was used. The resulting report
contained contributions of protomer B residues for binding to the dimer interface of
protomer A with electrostatic and Van der Waals interaction energy stratification.
5.6.4 Heterodimer Interaction Energy Calculations
Each monomer was combined into the window using Discovery Studio 3.0 and was
minimized as previously described in section 5.6.3. The interaction energy was then
calculated for one entire protein in relation to the other entire protein. The calculation
was then reversed to get contributions of the other for heterodimer formation.
Conclusions were then assessed by narrowing the field of view to the contributions of
each protein’s dimer interface and were then analyzed in conjunction with the homology
model of the heterodimer.
5.6.5 Synthesis of hRIPK3 Peptide
See section 3.4.1 Standard Fmoc Chemistry Solid Phase Peptide Synthesis Protocol
for details.
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FIGURE 5.1: HOMODIMER DIF INTERACTION ENERGY CALCULATIONS
Homodimers were either taken from the protein data bank or are a
homology model for hRIPK3 based on the mRIPK3 crystal structure. The
homodimers were minimized using Discovery Studios 3.0 and the
interaction energy was calculated for the second monomer in each
complex. Energies are heat mapped with the most favorable interactions
presented in green and least favorable in red.
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hRIPK3
Residue
IE
(kcal/mol)
M52
-1.0
A53
-16.1
S54
-3.9
L55
-14.3
D56
-34.2
N57
-5.5
E58
-19.0
F59
-1.2
V60
-1.0
L61
0.3
R62
16.2
L63
-3.7
E64
-18.4
G65
-0.2

BRAF
Residue
IE
(kcal/mol)
L505
0.3
R506
0.1
K507
1.4
T508
0.7
R509
-55.9
H510
-5.1
V511
-3.9
N512
-0.8
I513
-0.8
L514
1.0
L515
-5.6
F516
3.5
M517
-2.6
G518
-0.2

FIGURE 5.2:
BRAF/hRIPK3 HETERODIMER INTERACTION
ENERGY CALCULATIONS: The heterodimer for this experiment
was a combination of one BRAF protomer from PDB 4E26 and one
hRIPK3 protomer from the homology model previously described.
Interaction energy values represent the specific residue’s
calculated value for the opposing protomer as a whole and is not
confined to the opposing protomer’s dimer interface.
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FIGURE 5.3: HUMAN RIPK3 HOMOLOGY MODEL AND BRAF CRYSTAL
STRUCTURE: A.) Crystal structure (PDB 4E26) of BRAF monomer with dimer
interface (DIF) in blue. B.) Homology model of hRIPK3 based on mRIPK3 crystal
structure (PDB 4M66) with DIF in purple. C.) Overlay of BRAF and hRIPK3 dimers
with DIFs in respective colors and key binding Arg sidechain visible.
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FIGURE 5.4: HETERODIMER OF BRAF AND hRIPK3: Computational modeling of
the dimer interface of the BRAF/hRIPK3 heterodimer with the BRAF DIF in blue
and the hRIPK3 DIF in red. The major contributing interaction from BRAF include
R509 in yellow. The major contributing interaction from hRIPK3 is D56 (orange)
and the minor factors A53, L55, E58, and D64 are represented in green.
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FIGURE 5.5: EXAMPLES OF CYCLIC PEPTIDES WITH POTENTIAL ALTERNATIVE
CYCLIZATION METHODS
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APPENDIX A
CHARACTERIZATION OF PEPTIDES
TABLE A.1: LCMS CHARACTERIZATION OF SYNTHETIC PEPTIDES
Peptide
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1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Column
Dimensions
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm

Method

Flow Rate

5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min

1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min

Retention
Time
20.3
19.3
20.7
17.1
19.9
19.4
18.2
17.7
20.2
18.3
17.0
18.6
20.1
17.7
17.7
17.7
17.0
18.9

Theoretical
MW
2205.6
2185.5
2205.6
2163.5
2178.6
2162.6
2219.6
2175.6
2215.7
2177.6
2163.6
2205.6
2219.6
2173.6
1854.3
1740.2
1797.2
1796.2

Observed
MW
2205.0
2186.1
2205.9
2163.3
2178.2
2162.4
2219.4
2175.3
2215.3
2177.2
2163.4
2205.4
2219.4
2173.3
1853.9
1739.9
1797.5
1796.1

Peptide
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19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

Column
Dimensions
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm

Method

Flow Rate

5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-95% ACN/water/0.1% TFA/30 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-65% ACN/water/0.1% TFA/25 min
5-95% ACN/water/0.1% FA/20 min
5-95% ACN/water/0.1% FA/20 min
5-65% ACN/water/0.1% TFA/25 min
5-95% ACN/water/0.1% TFA/30 min
5-95% ACN/water/0.1% TFA/30 min
5-95% ACN/water/0.1% TFA/30 min
5-95% ACN/water/0.1% TFA/30 min
5-95% ACN/water/0.1% TFA/30 min
5-95% ACN/water/0.1% FA/20 min
5-95% ACN/water/0.1% FA/20 min
5-95% ACN/water/0.1% FA/20 min
5-95% ACN/water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min

1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min

Retention
Time
14.8
15.0
15.5
15.9
19.4
13.6
17.5
17.8
16.4
13.9
15.3
20.5
20.0
17.5
17.2
17.7
17.4
18.2
17.6
17.2
18.3
17.6
17.1
18.9
18.4

Theoretical
MW
1839.3
1755.2
1713.1
1740.1
1712.1
1731.2
1754.2
1755.2
1755.2
1721.1
1737.1
1886.3
1872.3
1684.1
1707.0
1722.1
1664.0
1679.1
1683.1
1715.1
1679.1
1665.1
1693.1
1281.6
1279.6

Observed
MW
1839.7
1755.2
1712.4
1740.2
1712.0
1731.5
1754.2
1755.3
1755.5
1721.3
1737.2
1888.0
1872.0
1683.5
1708.0
1724.0
1664.0
1680.0
1682.0
1714.9
1680.0
1668.0
1693.0
1281.3
1279.3

Peptide
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44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

Column
Dimensions
2.1 x 100 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm
4.6 x 250 mm

Method

Flow Rate

10-95% ACN /water/0.1%FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min
5-95% ACN /water/0.1% FA/20 min

0.2 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min

Retention
Time
1.8
24.0
24.4
22.1
22.4
21.2
19.7
20.8
25.0
22.1
23.1
24.1
20.3
18.9
25.8

Theoretical
MW
719.8
1403.7
1417.7
1431.8
1445.8
1325.7
1325.7
1325.7
1046.3
1014.2
960.2
862.1
1592.8
1826.3
1029.3

Observed
MW
720.0
1403.3
1417.3
1431.4
1445.5
1325.6
1325.6
1325.6
1046.1
1014.1
960.1
862.0
1592.4
1828.0
1029.1

APPENDIX B
TC-NMR DATA

FIGURE B.1: TC-NMR SPECTRA OF PEPTIDE 17: NMR spectra were taken from 295-320ᵒ K
showing that all amide protons shifted at temperature-dependent rate faster than that
associated with IMHBs.
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